0001144204-19-040066.txt : 20190814 0001144204-19-040066.hdr.sgml : 20190814 20190814160646 ACCESSION NUMBER: 0001144204-19-040066 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190814 DATE AS OF CHANGE: 20190814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000910267 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-13341 FILM NUMBER: 191026309 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502444990 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 10-Q 1 tv526706_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019.

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number 001-13341

Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	94-3171940
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

400 Oyster Point Blvd., Suite 505,

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

(650) 244-4990

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x
Smaller reporting company	¨	Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		TTNP		Nasdaq Capital Market

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class		Outstanding at August 9, 2019
Common Stock, par value $0.001		15,741,571

Titan Pharmaceuticals, Inc.

Index to Form 10-Q

Part I. Financial Information

Item 1.	Financial Statements (unaudited)

	Condensed Balance Sheets as of June 30, 2019 and December 31, 2018	1

	Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2019 and 2018	2

	Condensed Statements of Stockholders’ Equity (Deficit) for the six months ended June 30, 2019 and 2018	3

	Condensed Statements of Cash Flows for the six months ended June 30, 2019 and 2018	4

	Notes to Condensed Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17

Item 4.	Controls and Procedures	17

Part II. Other Information

Item 1A.	Risk Factors	18

Item 6.	Exhibits	18

SIGNATURES		20

Part I. Financial Information

Item 1. Financial Statements

TITAN PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS

(in thousands, except per share data)

	June 30, 2019			December 31, 2018
	(unaudited)			(Note 1)
Assets
Current assets:
Cash and cash equivalents	$	2,292		$	9,295
Restricted cash		—			361
Receivables		1,140			1,737
Inventory		1,317			1,262
Contract assets		—			99
Prepaid expenses and other current assets		744			547
Total current assets		5,493			13,301
Property and equipment, net		754			794
Operating lease right-of-use asset		514			—
Total assets	$	6,761		$	14,095

Liabilities and Stockholders’ (Deficit) Equity
Current liabilities:
Accounts payable	$	1,025		$	1,526
Accrued clinical trials expenses		504			620
Accrued sales allowances		830			—
Other accrued liabilities		397			466
Deferred revenue		—			313
Operating lease liability, current		253			—
Current portion of long-term debt		1,333			527
Total current liabilities		4,342			3,452
Operating lease liability, non-current		292			—
Long-term debt		2,698			3,787
Derivative liability		—			25
Total liabilities		7,332			7,264

Stockholders’ (deficit) equity:
Common stock, $0.001 par value per share: 125,000 shares authorized; 14,262 and 13,010 shares issued and outstanding at June 30, 2019 and December 31, 2018		14			13
Additional paid-in capital		341,708			339,397
Accumulated deficit		(342,293	)		(332,579	)
Total stockholders’ (deficit) equity		(571	)		6,831
Total liabilities and stockholders’ (deficit) equity	$	6,761		$	14,095

See Notes to Condensed Financial Statements

TITAN PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amount)

(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Revenues:
License revenue	$	—		$	2,593		$	313		$	3,657
Product revenue		304			75			621			75
Grant revenue		198			—			513			—
Total revenues		502			2,668			1,447			3,732
Operating expenses:
Cost of goods sold		246			70			550			70
Research and development		1,907			1,857			3,751			3,713
Selling, general and administrative		3,231			1,380			6,313			2,995
Total operating expenses		5,384			3,307			10,614			6,778
Loss from operations		(4,882	)		(639	)		(9,167	)		(3,046	)
Other expense:
Interest expense, net		(253	)		(230	)		(499	)		(428	)
Loss on debt extinguishment		(65	)		—			(65	)		—
Other income, net		3			—			17			—
Other expense, net		(315	)		(230	)		(547	)		(428	)
Net loss and comprehensive loss	$	(5,197	)	$	(869	)	$	(9,714	)	$	(3,474	)
Basic and diluted net loss per common share	$	(0.38	)	$	(0.25	)	$	(0.73	)	$	(0.98	)
Weighted average shares used in computing basic and diluted net loss per common share		13,576			3,534			13,397			3,534

See Notes to Condensed Financial Statements

TITAN PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands)

(unaudited)

	Common Stock				Additional Paid-In		Accumulated
	Shares		Amount		Capital		Deficit			Equity (Deficit)
Balances at December 31, 2018		13,010	$	13	$	339,397	$	(332,579	)	$	6,831
Net loss		—		—		—		(4,517	)		(4,517	)
Issuance of common stock upon exercises of warrants, net		404		—		605		—			605
Stock-based compensation		—		—		136		—			136
Balances at March 31, 2019		13,414	$	13	$	340,138	$	(337,096	)	$	3,055
Net loss		—		—		—		(5,197	)		(5,197	)
Issuance of common stock upon exercises of warrants, net		70		—		105		—			105
Issuance of common stock upon conversion of convertible loan		448		1		649		—			650
Issuance of common stock in at-the-market offerings, net		330		—		466		—			466
Stock-based compensation		—		—		350		—			350
Balances at June 30, 2019		14,262	$	14	$	341,708	$	(342,293	)	$	(571	)

	Common Stock				Additional Paid-In		Accumulated
	Shares		Amount		Capital		Deficit			Equity (Deficit)
Balances at December 31, 2017		3,534	$	4	$	324,124	$	(323,271	)	$	857
Net loss		—		—		—		(2,605	)		(2,605	)
Issuance of warrants to purchase common stock, net		—		—		470		—			470
Stock-based compensation		—		—		432		—			432
Balances at March 31, 2018		3,534	$	4	$	325,026	$	(325,876	)	$	(846	)
Net loss		—		—		—		(869	)		(869	)
Stock-based compensation		—		—		402		—			402
Balances at June 30, 2018		3,534	$	4	$	325,428	$	(326,745	)	$	(1,313	)

See Notes to Condensed Financial Statements

TITAN PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Six Months Ended June 30,
	2019			2018
Cash flows from operating activities:
Net loss	$	(9,714	)	$	(3,474	)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization		123			224
Non-cash interest expense		335			208
Stock-based compensation		486			834
Other		8			—
Changes in operating assets and liabilities:
Receivables		597			(124	)
Inventory		(55	)		(1,317	)
Contract assets		99			(72	)
Prepaid expenses and other assets		(197	)		(59	)
Accounts payable		(501	)		(246	)
Accrued sales allowances		830			—
Other accrued liabilities		(155	)		232
Deferred revenue		(313	)		939
Net cash used in operating activities		(8,457	)		(2,855	)

Cash flows from investing activities:
Purchases of property and equipment		(83	)		(53	)
Net cash used in investing activities		(83	)		(53	)

Cash flows from financing activities:
Net proceeds from the exercises of common stock warrants		710			—
Net proceeds from the issuance of common stock in an at-the-market offering		466			—
Payments of long-term debt		—			(3,000	)
Net cash provided by (used in) financing activities		1,176			(3,000	)
Net decrease in cash and cash equivalents		(7,364	)		(5,908	)
Cash, cash equivalents and restricted cash at beginning of period		9,656			7,883
Cash, cash equivalents and restricted cash at end of period	$	2,292		$	1,975
Supplemental disclosure of cash flow information:
Interest paid	$	219		$	234
Warrants issued	$	—		$	470
Non-cash conversion of Molteni Convertible Loan	$	650		$	—

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown in the condensed statement of cash flows:

	June 30,
	2019		2018
Cash and cash equivalents	$	2,292	$	1,614
Restricted cash		—		361
Cash, cash equivalents and restricted cash shown in the statement of cash flows	$	2,292	$	1,975

See Notes to Condensed Financial Statements

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

Organization and Summary of Significant Accounting Policies

The Company

We are a pharmaceutical company developing therapeutics for the treatment of select chronic diseases utilizing our proprietary long-term drug delivery platform, ProNeura™, and we are currently transitioning to a commercial stage enterprise having re-acquired Probuphine® in May 2018, our first product approved in the U.S. for the maintenance treatment of opioid dependence. We operate in only one business segment, the development and commercialization of pharmaceutical products.

In January 2019, pursuant to prior stockholder authorization, our Board effected a reverse split of the outstanding shares of our common stock at a ratio of one share for every six shares then outstanding (the “Reverse Split”). Pursuant to their respective terms, the number of shares underlying our outstanding options and warrants was reduced and their respective exercise prices increased by the Reverse Split ratio. The number of shares of common stock authorized and the par value of $0.001 per share did not change as a result of the Reverse Split. All share and per share amounts contained in this Form 10-Q give retroactive effect to the Reverse Split.

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019, or any future interim periods.

The balance sheet at December 31, 2018 is derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals, Inc. Annual Report on Form 10-K/A for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (“SEC”).

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. The accompanying financial statements have been prepared assuming we will continue as a going concern.

In August 2019, we received net proceeds of approximately $1.8 million for the sale of 2,852,314 shares of our common stock (and pre-funded warrants in lieu thereof) and warrants to purchase 2,852,314 shares of our common stock (see Note 7). As of June 30, 2019, we had cash and cash equivalents of approximately $2.3 million, which, we believe, together with the net proceeds from the August 2019 equity financing, is sufficient to fund our planned operations through October 2019. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful.

Going concern assessment

We assess going concern uncertainty in our condensed financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the “look-forward period” as defined by Accounting Standard Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS - Continued

(unaudited)

Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Quarterly Report on Form 10-Q for the six months ended June 30, 2019, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there is substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.

Use of Estimates

The preparation of these unaudited condensed financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to warrants issued in equity financing, research and development expenses, income taxes, inventories, revenues, contingencies and litigation and share-based compensation. We base our estimates on historical experience, information received from third parties and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ significantly from those estimates under different assumptions or conditions.

Revenue Recognition

We generate revenue principally from the sale of Probuphine in the U.S., collaborative research and development arrangements, technology licenses and sales, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price.

In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.

Net Product Revenue

We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue is subject to a variety of deductions in the forms of variable consideration, which include rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration is estimated using the most-likely amount method, which is the single most-likely outcome under a contract and is typically at stated contractual rates. The actual outcome of this variable consideration may materially differ from our estimates. From time to time, we will adjust our estimates of this variable consideration when trends or significant events indicate that a change in estimate is appropriate to reflect the actual experience. Additionally, we will continue to assess the estimates of our variable consideration as we continue to accumulate additional historical data. Changes in the estimates of our variable consideration could materially affect our financial statements.

Returns – Consistent with the provisions of ASC 606, we estimate returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which may impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement. During the six months ended June 30, 2019, we entered into agreements with large national specialty pharmacies with a distribution channel different from that of our existing customers and, therefore, the related reserves have unique considerations. We will continue to evaluate the activities with these specialty pharmacies during upcoming quarters and will update the related reserves accordingly.

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS - Continued

(unaudited)

Rebates – Our provision for rebates is estimated based on our customers’ contracted rebate programs and our historical experience of rebates paid.

Discounts –The provision is estimated based upon invoice billings, utilizing historical customer payment experience.

The following table provides a summary of activity with respect to our product returns, and discounts and rebates, which are included on our condensed consolidated balance sheets within accrued sales allowances (in thousands):

	Product Returns Allowance			Discounts and Rebates Allowance			Total
Balance at December 31, 2018	$	33		$	48		$	81
Provision		766			156			922
Payments/credits		(40	)		(133	)		(173	)
Balance at June 30, 2019	$	759		$	71		$	830

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process.

We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.

Transaction Price

We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.

At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.

For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied).

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS - Continued

(unaudited)

Allocation of Consideration

As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach.

Timing of Recognition

Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.

Research and Development Costs and Related Accrual

Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (“CRO”) activities, sponsored research studies, product registration, patent application and prosecution, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.

Leases

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update, or ASU, No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. We adopted the standard effective January 1, 2019.

We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our condensed balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. We no longer recognize deferred rent on our condensed balance sheet.

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS - Continued

(unaudited)

Recent Accounting Pronouncements

Accounting Standards Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Topic 842 requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. Effective January 1, 2019, we adopted the provisions under Topic 842 using a modified retrospective transition approach without adjusting comparative periods. Additionally, as permitted by Topic 842, we elected to apply the following practical expedients: (i) not to reassess whether any expired or existing contracts are or contain leases or the classification of any expired or existing leases and (ii) not to apply the recognition requirements to short-term leases. As a result of this adoption, we recorded operating lease right-of-use asset and operating lease liability associated with our office lease located on 400 Oyster Point Blvd., South San Francisco, California, in our condensed balance sheet as of March 31, 2019. We used a discount rate of 12%, which reflects our borrowing rate as of the adoption date, to measure the present value of future lease payments to determine the fair value of our operating lease right-of-use asset and liability. Our office lease expires in June 2021 and we did not include an estimated renewal in the calculation of our operating lease right-of-use asset and liability as we believe that it is less than probable we will renew our office lease. Our adoption of Topic 842 did not result in any cumulative adjustment to the balance of our accumulated deficit as of January 1, 2019. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term, which is consistent with Topic 840.

The following table presents maturities of our operating lease (in thousands):

2019 (6 months)	$	153
2020		308
2021		155
Total minimum lease payments (base rent)		616
Less: imputed interest		(71	)
Total operating lease liabilities	$	545

In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to nonemployees with the guidance applicable to grants to employees. Under the new standard, equity-classified share-based payment awards issued to nonemployees are measured on the grant date, instead of the current requirement to remeasure the awards through the performance completion date. We adopted ASU 2018-07 during the three months ended March 31, 2019 using the prospective approach. The adoption of ASU 2018-07 did not have any material impact to our condensed financial statements.

In August 2018, the SEC published Release No. 33-10532, Disclosure Update and Simplification, or DUSTR, which adopted amendments to certain disclosure requirements that have become redundant, duplicative, overlapping, outdated or superseded, in light of other SEC disclosure requirements, GAAP, or changes in the information environment. While most of the DUSTR amendments eliminate updated or duplicative disclosure requirements, the final rule amends the interim financial statement requirements to include a reconciliation of changes in stockholders’ equity (deficit) in the notes or as a separate statement for each period for which a statement of comprehensive income (loss) is required to be filed. The new interim reconciliation of changes in stockholders’ equity (deficit) for the six months ended June 30, 2019 and 2018 is included herein.

Accounting Standards Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses, which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective for us in our interim period ending March 31, 2020. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We do not expect the adoption of this ASU to have any significant impact on our quarterly or annual disclosures.

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS - Continued

(unaudited)

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that Is a Service Contract. The ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Adoption of the ASU is either retrospective or prospective. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU No. 2018-15 on our condensed financial statements.

Subsequent Events

We have evaluated events that have occurred after June 30, 2019 and through the date that our condensed financial statements are issued. See Note 7. “Subsequent Events.”

Fair Value Measurements

Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, approximate their fair values due to the short-term nature of these instruments. Our investments in money market funds are classified within Level 1 of the fair value hierarchy. Our derivative liability is classified within level 3 of the fair value hierarchy because the fair value is calculated using significant judgment based on our own assumptions in the valuation of this liability.

At June 30, 2019 and December 31, 2018, the fair value of our investments in money market funds were approximately $1.6 million and approximately $8.9 million, respectively, which are included within our cash and cash equivalents in our condensed balance sheets.

Stock Plans

In January 2019, our stockholders approved an amendment to the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan to increase the number of shares authorized for awards thereunder from 583,334 to 1,666,667.

In January 2019, our stockholders approved a repricing of 122,115 fully-vested stock options with exercise prices in excess of $21.00 held by employees and consultants other than the named executive officers or members of the Board. The effected options were repriced at $1.55. As a result of the repricing of these stock options, we incurred a total of approximately $136,000 of additional stock-based compensation expense during the six months ended June 30, 2019, of which approximately $77,000 was recorded within research and development and approximately $59,000 within selling, general and administrative in our condensed statement of operations and comprehensive loss.

The following table summarizes the stock-based compensation expense recorded for awards under our stock option plans (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Research and development	$	14	$	156	$	91	$	318
Selling, general and administrative		336		246		395		516
Total stock-based compensation	$	350	$	402	$	486	$	834

We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the fair value of our stock options:

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Weighted-average risk-free interest rate		2.1	%		2.9	%		2.2	%		2.7	%
Expected dividend payments		—			—			—			—
Expected holding period (years) ¹		5.9			6.4			5.4			6.4
Weighted-average volatility factor ²		0.93			0.91			0.94			0.89
Estimated forfeiture rates for options granted ³		21	%		25	%		21	%		26	%

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS - Continued

(unaudited)

(1)

Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.

(2)

Weighted average volatility is based on the historical volatility of our common stock.

(3)

Estimated forfeiture rates are based on historical data.

The following table summarizes option activity:

	Options (in thousands)			Weighted Average Exercise Price per share		Weighted Average Remaining Option Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at January 1, 2019		665		$	17.94		6.44	$	4.0
Granted		854			1.64
Cancelled		(217	)		26.49
Outstanding at June 30, 2019		1,302			5.82		8.47		0.8
Exercisable at June 30, 2019		669			9.83		7.23		0.1

As of June 30, 2019, there was approximately $0.7 million of total unrecognized compensation expense related to non-vested stock options. This expense was expected to be recognized over a weighted-average period of approximately 1.75 years.

Net Loss Per Share

The table below presents common shares underlying stock options, warrants and convertible loans (see Note 5) that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Weighted-average anti-dilutive common shares resulting from options		1,124		610		894		555
Weighted-average anti-dilutive common shares resulting from warrants		277		247		257		288
Weighted-average anti-dilutive common shares resulting from convertible loans		333		—		333		—
		1,734		857		1,484		843

Molteni Purchase Agreement

On March 21, 2018, we entered into a purchase agreement (“Molteni Purchase Agreement”) with L. Molteni & C. Dei Frattelli Alitti Società Di Esercizio S.P.A. (“Molteni”) pursuant to which Molteni acquired the European intellectual property related to Probuphine, including the marketing authorization application under review by the European Medicines Agency (“EMA”), and gained the exclusive right to commercialize the Probuphine product supplied by us in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa (the “Molteni Territory”).

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS - Continued

(unaudited)

We received an initial payment of €2.0 million (approximately $2.4 million) for the purchased assets and will receive additional potential payments upon achievement of certain regulatory and product label milestones. Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory in percentages ranging from the low-teens to the mid-twenties.

We concluded that the performance obligations identified in the Molteni Purchase Agreement included the transfer of the intellectual property and our efforts towards an approval by the EMA and other regulatory bodies. The initial payment was allocated between the property transfer and our EMA efforts as set forth below.

We used the expected cost-plus approach to estimate the standalone selling price of approximately $1.4 million related to our efforts towards an approval by the EMA and other regulatory bodies (“Titan Services”). This includes employee related expenses as well as other manufacturing, regulatory and clinical costs, which are incurred as part of our efforts. As of March 31, 2019, we fully recognized the revenue associated with the Titan Services under the Molteni Purchase Agreement as we completed the Titan Services.

The following table presents changes in contract assets and liabilities during the six months ended June 30, 2019 (in thousands):

(in thousands)	Beginning Balance		Deductions			Ending Balance
Contract assets	$	99	$	(99	)	$	—
Contract liability:
Deferred revenue	$	313	$	(313	)	$	—

In August 2018, we entered into an amendment (the “Amendment”) to the Molteni Purchase Agreement. Under the Amendment, Molteni made an immediate payment of €950,000 (approximately $1.1 million) and a convertible loan of €550,000 (approximately $0.6 million) (“Molteni Convertible Loan”) (see Note 5) to us, both in exchange for the elimination of an aggregate of €2.0 million (approximately $2.3 million) of regulatory milestones provided for in the Molteni Purchase Agreement that are potentially payable in 2019, at the earliest. We concluded that the approximately $1.1 million immediate payment by Molteni reflected a milestone payment with no additional obligations to us and, therefore, was recognized as revenue during the year ended December 31, 2018.

Debt Agreements

Horizon and Molteni Loan

In July 2017, we entered into a venture loan and security agreement that was subsequently amended in February 2018, (“Horizon Loan Agreement”) with Horizon Technology Finance Corporation (“Horizon”).

Repayment of the loans is on an interest-only basis through December 31, 2019, followed by monthly payments of principal and accrued interest for the balance of the 46-month term. The loans bear interest at a floating coupon rate of one-month LIBOR (floor of 1.10%) plus 8.40%. A final payment equal to 5.0% of each loan tranche will be due on the scheduled maturity date for such loan. In addition, if we repay all or a portion of the loan prior to the applicable maturity date, we will pay Horizon a prepayment penalty fee, based on a percentage of the then outstanding principal balance, equal to 4% if the prepayment occurs during the interest-only payment period, 3% if the prepayment occurs during the 12 months following such period, and 2% thereafter.

In connection with the Horizon Loan Agreement, we issued Horizon warrants that are currently exercisable to purchase an aggregate of 366,668 shares of our common stock at an exercise price per share of $1.50.

In March 2018, we entered into an Amended and Restated Venture Loan and Security Agreement (the “Restated Loan Agreement”) with Horizon and Molteni pursuant to which Horizon assigned approximately $2.4 million of the $4.0 million outstanding principal balance of the loan to Molteni and Molteni was appointed as the collateral agent and assumed majority and administrative control of the loan. Under the Restated Loan Agreement, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $7.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $7.20 and repay the $1.6 million balance of Horizon’s loan amount. In connection with the Restated Loan Agreement, we issued warrants to purchase an aggregate of 6,667 shares of our common stock with an exercise price per share of $7.20 to Horizon. As of June 30, 2019, the loan from Molteni under the Restated Loan Agreement was convertible into 333,333 shares of our common stock.

TITAN PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS - Continued

(unaudited)

In consideration of Molteni’s entry into the Restated Loan Agreement and the Purchase Agreement, on March 21, 2018, we entered into a rights agreement (the “Rights Agreement”) with Molteni pursuant to which we agreed to (i) issue Molteni seven-year warrants to purchase 90,000 shares of our common stock at an exercise price of $7.20 per share (the “Molteni Warrants”), (ii) provide Molteni customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon conversion of its loan and exercise of the Molteni Warrants, (iii) designate one member of our board of directors following conversion of the loan in full and (iv) provide board observer rights to Molteni if it has not designated a board nominee as well as certain information rights.

Molteni Convertible Loan

In connection with the Amendment to the Molteni Purchase Agreement (see Note 4), in June 2019, the Molteni Convertible Loan, together with unpaid accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum, was converted into 448,287 shares of our common stock at $1.50 per share upon the receipt of EMA approval of Sixmo. As a result, we recorded approximately $0.1 million of loss on debt extinguishment. There was no outstanding balance under the Molteni Convertible Loan as of June 30, 2019.

Stockholders’ Equity

At-the-Market Offering (the “ATM”)

In April 2019, we implemented the ATM for the sale of up to $8.6 million of our common stock. During the three months ended June 30, 2019, we issued a total of 329,656 shares of our common stock at a weighted-average price of $1.60 per share for total net proceeds of approximately $0.5 million under the ATM. In August 2019, in connection with the financing described in Note 7, we reduced the dollar amount that can be sold under ATM to $4.0 million.

Subsequent Events

In August 2019, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single accredited institutional investor (the “Purchaser”) pursuant to which we issued 1,480,000 shares of our common stock and pre-funded warrants to purchase 1,372,314 shares of our common stock with an exercise price of $0.01 per share (the “Pre-funded Warrants”) in a registered direct offering and warrants to purchase 2,852,314 shares of our common stock with an exercise price of $1.07 per share (the “Placement Warrants”) in a concurrent private placement. The Pre-Funded Warrants were issued in lieu of common stock in order to ensure the Purchaser did not exceed certain beneficial ownership limitations. The Placement Warrants will be exercisable commencing six months from the date of issuance and will expire five years following the initial exercise date.

The terms of the Purchase Agreement include certain restrictions on our future stock offerings and granted to the Purchaser a participation right in future financings. We received net proceeds of approximately $1.8 million, after deduction of underwriting fees and other offering expenses.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Statements in the following discussion and throughout this report that are not historical in nature are “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. You can identify forward-looking statements by the use of words such as “expect,” “anticipate,” “estimate,” “may,” “will,” “should,” “intend,” “believe,” and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described under Item 1A “Risk Factors.” We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes.

References herein to “we,” “us,” “Titan,” and “our company” refer to Titan Pharmaceuticals, Inc. and its subsidiaries unless the context otherwise requires.

Overview

We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We have been transitioning to a commercial stage enterprise following the reacquisition of Probuphine® (buprenorphine) implant, or Probuphine, on May 25, 2018 from our former licensee. Probuphine is the first product based on our ProNeura technology approved in the U.S., Canada and, in June 2019, the European Union for the maintenance treatment of opioid use disorder, or OUD, in eligible patients. Since the reacquisition, we have been implementing a strategic plan aimed at building the foundation to support an effective U.S. product relaunch targeted at select OUD market segments best suited for Probuphine, including the establishment of a small experienced commercial team and the engagement of new strategic partners in the product order and distribution process.

ProNeura consists of a small, solid rod made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. The resulting product is a solid matrix that is placed subdermally, normally in the inside part of the upper arm in a short physician office based outpatient procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released continuously through the process of diffusion-controlled dissolution, resulting in a steady rate of release generally similar to intravenous administration thereby avoiding the fluctuating peak and trough levels of oral dosing that often pose problems in many disease settings. We believe that our ProNeura long term drug delivery platform has the potential to be used in the treatment of other chronic conditions where maintaining stable, around the clock blood levels of a medication may benefit the patient and improve medical outcomes. While our primary focus is on the commercialization of Probuphine, we are also engaged in early stage research and development efforts on a product pipeline based on this platform technology.

We operate in only one business segment, the development and commercialization of pharmaceutical products. We make available free of charge through our website, www.titanpharm.com, our periodic reports as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

Recent Accounting Pronouncements

See Note 1 to the accompanying unaudited condensed financial statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q for information on recent accounting pronouncements.

Results of Operations for the Three and Six Months June 30, 2019 and 2018

Revenues

	Three Months Ended June 30,							Six Months Ended June 30,
	2019		2018		Change			2019		2018		Change
	(In thousands)
Revenues:
License revenue	$	—	$	2,593	$	(2,593	)	$	313	$	3,657	$	(3,344	)
Product revenue		304		75		229			621		75		546
Grant revenue		198		—		198			513		—		513
Total revenues	$	502	$	2,668	$	(2,166	)	$	1,447	$	3,732	$	(2,285	)

The decrease in revenues for the three and six months ended June 30, 2019 was primarily due to one-time payments in 2018 associated with Probuphine, partially offset by grant revenue and higher product revenue. License revenues recognized for the three and six months ended June 30, 2018 were related to the sale of our European intellectual property rights to Molteni, the return of the Braeburn license and earned royalties while license revenue recognized for the six months ended June 30, 2019 was related to amortization of deferred revenue associated with the sale of our European intellectual property rights to Molteni. Our product revenues reflect net revenues generated from sales of our Probuphine product by us after the return of the commercialization rights from our former licensee in May 2018.

Operating Expenses

	Three Months Ended June 30,						Six Months Ended June 30,
	2019		2018		Change		2019		2018		Change
	(In thousands)
Operating expenses:
Cost of goods sold	$	246	$	70	$	176	$	550	$	70	$	480
Research and development		1,907		1,857		50		3,751		3,713		38
Selling, general and administrative		3,231		1,380		1,851		6,313		2,995		3,318
Total operating expenses	$	5,384	$	3,307	$	2,077	$	10,614	$	6,778	$	3,836

Cost of goods sold reflects costs and expenses associated with sales of our Probuphine product by us after reacquiring the product in May 2018.

The increase in our research and development expenses for the three months ended June 30, 2019 was primarily due to approximately $0.9 million of higher research and development expenses related to Probuphine, including the initiation of a phase 4 clinical trial, and our nalmafene product development program. These increases were partially offset by approximately $0.5 million of lower external research and development expenses related to our implant development programs and an approximately $0.3 million decrease in other research and development expenses. The increase in our research and development expenses for the six months ended June 30, 2019 was primarily due to approximately $1.7 million of higher external research and development expenses related to our product development programs for Probuphine, which includes the initiation of a phase 4 clinical trial, and the nalmafene product development program, partially offset by approximately $1.0 million of lower external research and development expenses related to the ropinirole implant program and other programs and approximately $0.6 million of lower other research and development expenses. Other research and development expenses include internal operating costs such as clinical research and development personnel-related expenses, clinical trials related travel expenses, and the allocation of facility and corporate costs. As a result of the risks and uncertainties inherently associated with pharmaceutical research and development and activities described elsewhere in this report, we are unable to estimate the specific timing and future costs of our research and development programs or the timing of material cash inflows, if any, from our product candidates.

The substantial increase in selling, general and administrative expenses for the three and six months ended June 30, 2019 was primarily due to expenses associated with commercialization of Probuphine, which resulted in increases in employee related expenses, consulting and professional fees, other outside services, travel costs and facilities related expenses. The increase in selling, general and administrative expenses for the three months ended June 30, 2019 was primarily attributable to increases in employee related expenses of approximately $0.8 million, consulting and professional fees of approximately $0.5 million, other outside services of approximately $0.3 million, travel related expenses of approximately $0.2 million and facilities related expenses of approximately $0.1 million. The increase in selling, general and administrative expenses for the six months ended June 30, 2019 was primarily attributable to increases in employee related expenses of approximately $1.3 million, consulting and professional fees of approximately $0.8 million, other outside services of approximately $0.6 million, travel related expenses of approximately $0.4 million and facilities related expenses of approximately $0.2 million.

Other Expense, Net

	Three Months Ended June 30,									Six Months Ended June 30,
	2019			2018			Change			2019			2018			Change
	(In thousands)
Other expense:
Interest expense, net	$	(253	)	$	(230	)	$	(23	)	$	(499	)	$	(428	)	$	(71	)
Loss on debt extinguishment		(65	)		—			(65	)		(65	)		—			(65	)
Other income, net		3			—			3			17			—			17
Other expense, net	$	(315	)	$	(230	)	$	(85	)	$	(547	)	$	(428	)	$	(119	)

The increase in other expense, net for the three month ended June 30, 2019 was primarily attributable to loss on debt extinguishment associated with the conversion of the Molteni Convertible Loan. The increase in other expense, net for the six months ended June 30, 2019 was primarily attributable to higher interest expense on higher outstanding loan balances and loss on debt extinguishment associated with the conversion of the Molteni Convertible Loan.

Net Loss and Net Loss per Share

Our net loss for the three months ended June 30, 2019 was approximately $5.2 million, or approximately $0.38 per share, compared to our net loss of approximately $0.9 million, or approximately $0.25 per share, for the comparable period in 2018. Our net loss for the six months ended June 30, 2019 was approximately $9.7 million, or approximately $0.73 per share, compared to our net loss of approximately $3.5 million, or approximately $0.98 per share, for the comparable period in 2018.

Liquidity and Capital Resources

We have funded our operations since inception primarily through the sale of our securities and the issuance of debt, as well as with proceeds from warrant and option exercises, corporate licensing and collaborative agreements, and government-sponsored research grants. At June 30, 2019, we had working capital of approximately $1.0 million compared to working capital of approximately $9.8 million at December 31, 2018.

In April 2019, we implemented the ATM for the sale of up to $8.6 million of our common stock. During the three months ended June 30, 2019, we received total net proceeds of approximately $0.5 million from the sale of 329,656 shares of our common stock at a weighted-average price of $1.60 per share under the ATM.

In June 2019, we issued 448,287 shares of our common stock upon the conversion of the Molteni Convertible Loan upon the receipt of the European Medicines Agency approval of Sixmo. See Note 5 of the Notes to Condensed Financial Statements in Item 1.

In August 2019, we entered into the Purchase Agreement pursuant to which we issued to the Purchaser 1,480,000 shares of our common stock and Pre-funded Warrants to purchase 1,372,314 shares of our common stock (in lieu of common stock) in a registered direct offering and Placement Warrants to purchase 2,852,314 shares of our common stock with an exercise price of $1.07 per share in a concurrent private placement. We received net proceeds of approximately $1.8 million, after deduction of underwriting fees and other offering expenses.

As of June 30, 2019, we had cash and cash equivalents of approximately $2.3 million, which we believe, together with the proceeds of the August 2019 financing, is sufficient to fund our planned operations through October 2019. We will require additional funds to finance our operations beyond such period. We are exploring several financing alternatives in addition to the ATM; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful.

Sources and Uses of Cash

	Six Months Ended June 30,
	2019			2018
	(In thousands)
Net cash used in operating activities		(8,457	)		(2,855	)
Net cash used in investing activities		(83	)		(53	)
Net cash provided by (used in) financing activities		1,176			(3,000	)
Net decrease in cash and cash equivalents		(7,364	)		(5,908	)

Net cash used in operating activities for the six months ended June 30, 2019 consisted primarily of our net loss of approximately $9.7 million. This was partially offset by approximately $0.3 million related to net changes in operating assets and liabilities and non-cash charges of approximately $0.5 million related to stock-based compensation, approximately $0.3 million related to interest expense, approximately $0.1 million related to depreciation and amortization. Net cash used in operating activities for the six months ended June 30, 2018 consisted primarily of the net loss for the period of approximately $3.5 million and approximately $0.6 million related to net changes in other operating assets and liabilities. This was offset, in part, by non-cash charges of approximately $0.8 million related to stock-based compensation, approximately $0.2 million related to depreciation and amortization and $0.2 million related to non-cash interest expense. Uses of cash in operating activities were primarily to fund commercialization, product development programs and administrative expenses.

Cash used in investing activities was primarily related to purchases of equipment for both the six months ended June 30, 2019 and 2018.

Net cash provided by financing activities for the six months ended June 30, 2019 consisted of approximately $0.7 million of net proceeds from the exercises of warrants to purchase our common stock and approximately $0.5 million of net proceeds from the issuance of our common stock under at-the-market offerings (the “ATM”). Net cash used in financing activities for the six months ended June 30, 2018 consisted of $3.0 million for the repayment of long-term debt.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our market risk disclosures set forth in our Annual Report on Form 10-K/A for the year ended December 31, 2018 have not materially changed.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our President and Chief Executive Officer, being our principal executive and financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act as of June 30, 2019, the end of the period covered by this report, and has concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our principal executive and principal financial officer as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the six months ended June 30, 2019 that materially affected, or were reasonably likely to materially affect, our internal controls over financial reporting.

PART II

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K/A for the year ended December 31, 2018, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K/A are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Item 6. Exhibits

No.		Description
1.1		Underwriting Agreement between Titan Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners ⁽²⁵⁾
3.1.1		Amended and Restated Certificate of Incorporation of the Registrant, as amended ⁽⁵⁾
3.1.2		Certificate of Amendment to the Restated Certificate of Incorporation dated September 24, 2015 ⁽¹⁴⁾
3.1.3		Certificate of Amendment to the Restated Certificate of Incorporation dated January 23,2019 ⁽²⁶⁾
3.2		By-laws of the Registrant ⁽¹⁾
3.3		Certificate of Designation of Series A Convertible Preferred Stock ⁽²⁵⁾
4.1		Form of 2014 Class A Warrant( ¹³⁾
4.3		Form of 2014 Underwriter Warrant ⁽¹³⁾
4.4		Form of Lender Warrant ⁽¹⁸⁾
4.5		Form of Rights Agreement Warrant ⁽²⁰⁾
4.6		Warrant Agency Agreement between Titan Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company and Form of Offering Warrant ⁽²⁵⁾
4.7		Representative’s Purchase Warrant ⁽²⁵⁾
4.8		Form of Pre-funded Warrant ⁽³⁰⁾
4.9		Form of Placement Warrant ⁽³⁰⁾
10.1		2001 Non-Qualified Employee Stock Option Plan ⁽²⁾
10.2		2002 Stock Option Plan ⁽³⁾
10.3		Lease for the Registrant’s facilities, amended as of October 1, 2004 ⁽⁴⁾
10.4		Amendments to lease for Registrant’s facilities dated May 21, 2007 and March 12, 2009 ⁽⁵⁾
10.5		Amendment to lease for Registrant’s facilities dated June 15, 2010 ⁽⁶⁾
10.6±		License Agreement by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals Sprl, dated December 14, 2012 ⁽⁸⁾
10.7		Amendment dated May 28, 2013 to License Agreement by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals Sprl ⁽⁹⁾
10.8		Second Amendment dated July 2, 2013 to License Agreement by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals Sprl ⁽¹⁰⁾
10.9		Third Amendment dated November 12, 2013 to License Agreement by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals Sprl( ¹⁵⁾
10.10		Titan Pharmaceuticals, Inc. 2014 Incentive Plan ⁽¹²⁾
10.11		Titan Pharmaceuticals, Inc. Third Amended and Restated 2015 Omnibus Equity Incentive Plan⁽²⁶⁾
10.12		Controlled Equity Offering ^SM Sales Agreement, dated September 1, 2016, between Titan Pharmaceuticals, Inc. and Cantor Fitzgerald & Co. ⁽¹⁶⁾
10.13		Employment Agreement between Titan Pharmaceuticals, Inc. and Titan Pharmaceuticals, Inc. and Sunil Bhonsle ⁽¹⁷⁾
10.14		Employment Agreement between Titan Pharmaceuticals, Inc. and Titan Pharmaceuticals, Inc. and Marc Rubin ⁽¹⁷⁾
10.15		Venture Loan and Security Agreement, dated July 27, 2017, by and between Titan Pharmaceuticals, Inc. and Horizon Technology Finance Corporation ⁽¹⁸⁾
10.16		Amendment of Venture Loan and Security Agreement, dated February 2, 2018, by and between Titan Pharmaceuticals, Inc. and Horizon Technology Finance Corporation ⁽¹⁹⁾

10.17		Amended and Restated Venture Loan and Security Agreement, dated March 21, 2018, by and between Titan Pharmaceuticals, Inc., Horizon Technology Finance Corporation and L. Molteni & C. Dei Frattelli Alitti Società Di Esercizio S.P.A. ⁽²⁰⁾
10.18±		Asset Purchase, Supply and Support Agreement dated March 21, 2018, by and between Titan Pharmaceuticals, Inc. and L. Molteni & C. Dei Frattelli Alitti Società Di Esercizio S.P.A. ⁽²⁰⁾
10.19		Rights Agreement dated March 21, 2018, by and between Titan Pharmaceuticals, Inc. and L. Molteni & C. Dei Frattelli Alitti Società Di Esercizio S.P.A. ⁽²⁰⁾
10.20±		Termination and Transition Services Agreement dated May 25, 2018 by and between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals, Inc. ⁽²¹⁾
10.21±		Amendment to Asset Purchase, Supply and Support Agreement dated August 3, 2018, by and between Titan Pharmaceuticals, Inc. and L. Molteni & C. Dei Frattelli Alitti Società Di Esercizio S.P.A ⁽²²⁾
10.22±		Distribution and Sublicense Agreement dated February 1, 2016 as amended by agreement dated August 2, 2018 between Titan Pharmaceuticals, Inc. and Knight Therapeutics Inc. ⁽²³⁾
10.23		Amendment to lease for Registrant’s facility dated March 21, 2016 ⁽²³⁾
10.24		Amendment to Employment Agreement with Sunil Bhonsle dated August 9, 2018 ⁽²³⁾
10.25		Amendment to Employment Agreement with Marc Rubin dated August 9, 2018( ²³⁾
10.26		Unsecured Convertible Loan Agreement dated September 18, 2018 ⁽²⁴⁾
10.27		Employment Agreement between the Registrant and Katherine Beebe DeVarney ⁽²⁷⁾
10.28		Employment Agreement between the Registrant and Dane Hallberg ⁽²⁷⁾
10.29		Employment Agreement between the Registrant and Sunil Bhonsle⁽²⁸⁾
10.30		Employment Agreement between the Registrant and Marc Rubin⁽²⁸⁾
10.31		Sales Agreement dated April 25, 2019 between the Registrant and A.G.P./Alliance Global Partners⁽²⁹⁾
10.32		Form of Securities Purchase Agreement ⁽³⁰⁾
10.33		Placement Agency Agreement ⁽³⁰⁾
14.1		Code of Business Conduct and Ethics ⁽¹²⁾
31.1		Certification of the Principal Executive and Financial Officer pursuant to Rule 13(a)-14(a) of the Securities Exchange Act of 1934
32.1		Certification of the Principal Executive and Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

±	Confidential treatment has been granted as to certain portions of this exhibit.
(1)	Incorporated by reference from the Registrant’s Registration Statement on Form S-3 (File No. 333-21126).
(2)	Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2001.
(3)	Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2002.
(4)	Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2005.
(5)	Incorporated by reference from the Registrant’s Registration Statement on Form 10 filed on January 14, 2010.
(6)	Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the period ended June 30, 2010.
(7)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on April 10, 2012.
(8)	Incorporated by reference from the Registrant’s Current Report on Form 8-K/A filed on February 28, 2013.
(9)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 29, 2013.
(10)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on July 5, 2013.
(11)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on November 13, 2013.
(12)	Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013.
(13)	Incorporated by reference from the Registrant’s Registration Statement on Form S-1/A dated September 30, 2014.
(14)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on September 28, 2015.
(15)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on August 3, 2016.
(16)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on September 1, 2016.
(17)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on October 3, 2016.
(18)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on July 27, 2017.
(19)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on February 7, 2018.
(20)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on March 26, 2018.
(21)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 30, 2018.
(22)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on August 3, 2018.
(23)	Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the period ended June 30, 2018.
(24)	Incorporated by reference from the Registrant’s Current Report on Form 8-K dated September 20, 2018.
(25)	Incorporated by reference from the Registrant’s Current Report on Form 8-K dated September 25, 2018.
(26)	Incorporated by reference from the Registrant’s Current Report on Form 8-K dated January 25, 2019.
(27)	Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018.
(28)	Incorporated by reference from the Registrant’s Current Report on Form 8-K dated April 3, 2019.
(29)	Incorporated by reference from the Registrant’s Current Report on Form 8-K dated April 25, 2019.
(30)	Incorporated by reference from the Registrant’s Current Report on Form 8-K dated August 7, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TITAN PHARMACEUTICALS, INC.

Dated: August 14, 2019	By:	/s/ Sunil Bhonsle
	Name:	Sunil Bhonsle
	Title:	President and Chief Executive Officer (Principal Executive and Principal Financial Officer)

EX-31.1 2 tv526706_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Sunil Bhonsle, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Titan Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2019

	/s/ Sunil Bhonsle
Name:	Sunil Bhonsle
Title:	President and Chief Executive Officer
	(Principal Executive Officer and Principal
	Financial Officer)

EX-32.1 3 tv526706_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report on Form 10-Q of Titan Pharmaceuticals, Inc. (the “Company”) for the period ended June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2019

	/s/ Sunil Bhonsle
Name:	Sunil Bhonsle
Title:	President and Chief Executive Officer
	(Principal Executive Officer and Principal
	Financial Officer)

EX-101.INS 4 ttnp-20190630.xml XBRL INSTANCE DOCUMENT 0000910267 srt:MaximumMember ttnp:AtMarketOfferingMember 2019-08-01 2019-08-31 0000910267 srt:MaximumMember ttnp:AtMarketOfferingMember 2019-04-01 2019-04-30 0000910267 ttnp:AtMarketOfferingMember 2019-04-01 2019-06-30 0000910267 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2019-06-30 0000910267 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2019-03-31 0000910267 2019-03-31 0000910267 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2018-12-31 0000910267 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2018-06-30 0000910267 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2018-03-31 0000910267 2018-03-31 0000910267 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2017-12-31 0000910267 us-gaap:CommonStockMember 2019-06-30 0000910267 us-gaap:CommonStockMember 2019-03-31 0000910267 us-gaap:CommonStockMember 2018-12-31 0000910267 us-gaap:CommonStockMember 2018-06-30 0000910267 us-gaap:CommonStockMember 2018-03-31 0000910267 us-gaap:CommonStockMember 2017-12-31 0000910267 ttnp:AtMarketOfferingMember 2019-06-30 0000910267 us-gaap:StockCompensationPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000910267 us-gaap:StockCompensationPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000910267 us-gaap:StockCompensationPlanMember 2019-01-01 2019-06-30 0000910267 2018-01-01 2018-12-31 0000910267 ttnp:TwoThousandFifteenPlanMember 2019-01-31 0000910267 ttnp:TwoThousandFifteenPlanMember 2018-12-31 0000910267

2019-04-01

2018-03-21 0000910267 2018-03-21 0000910267 us-gaap:ManufacturedProductOtherMember 2019-04-01 2019-06-30 0000910267 us-gaap:LicenseAndServiceMember 2019-04-01 2019-06-30 0000910267 us-gaap:GrantMember 2019-04-01 2019-06-30 0000910267 us-gaap:ManufacturedProductOtherMember 2019-01-01 2019-06-30 0000910267 us-gaap:LicenseAndServiceMember 2019-01-01 2019-06-30 0000910267 us-gaap:GrantMember 2019-01-01 2019-06-30 0000910267 2018-08-01 2018-08-31 0000910267 us-gaap:ManufacturedProductOtherMember 2018-04-01 2018-06-30 0000910267 us-gaap:LicenseAndServiceMember 2018-04-01 2018-06-30 0000910267 us-gaap:GrantMember 2018-04-01 2018-06-30 0000910267 us-gaap:ManufacturedProductOtherMember 2018-01-01 2018-06-30 0000910267 us-gaap:LicenseAndServiceMember 2018-01-01 2018-06-30 0000910267 us-gaap:GrantMember 2018-01-01 2018-06-30 0000910267 2018-03-21 2018-03-21 0000910267 us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0000910267 ttnp:MolteniLoanMember 2018-03-31 0000910267 us-gaap:AccountingStandardsUpdate201602Member 2019-01-31 0000910267 us-gaap:EmployeeStockOptionMember 2019-06-30 0000910267 ttnp:HorizonTechnologyFinanceCorporationMember ttnp:VentureLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-07-01 2017-07-31 0000910267 ttnp:HorizonLoanMember 2019-01-01 2019-06-30 0000910267 ttnp:HorizonLoanMember 2018-03-31 0000910267 ttnp:MolteniLoanMember us-gaap:ConvertibleDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-06-30 0000910267 ttnp:HorizonTechnologyFinanceCorporationMember ttnp:VentureLoanMember 2017-07-01 2017-07-31 0000910267 ttnp:MolteniPurchaseAgreementMember 2019-01-01 2019-06-30 0000910267 ttnp:MolteniPurchaseAgreementMember 2019-06-30 0000910267 2018-08-31 0000910267 2019-01-31 0000910267 ttnp:NewHorizonWarrantsMember 2018-03-21 0000910267 ttnp:HorizonTechnologyFinanceCorporationMember 2017-07-31 0000910267 ttnp:PreFundedWarrantsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember ttnp:SecuritiesPurchaseAgreementMember 2019-08-31 0000910267 ttnp:PlacementWarrantsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember ttnp:SecuritiesPurchaseAgreementMember 2019-08-31 0000910267 ttnp:HorizonLoanMember 2018-03-21 0000910267 ttnp:HorizonTechnologyFinanceCorporationMember 2017-07-27 0000910267 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000910267 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000910267 2017-12-31 0000910267 2018-06-30 0000910267 us-gaap:WarrantMember 2019-04-01 2019-06-30 0000910267 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000910267 us-gaap:ConvertibleDebtSecuritiesMember 2019-04-01 2019-06-30 0000910267 us-gaap:WarrantMember 2019-01-01 2019-06-30 0000910267 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000910267 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-06-30 0000910267 us-gaap:WarrantMember 2018-04-01 2018-06-30 0000910267 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000910267 us-gaap:ConvertibleDebtSecuritiesMember 2018-04-01 2018-06-30 0000910267 us-gaap:WarrantMember 2018-01-01 2018-06-30 0000910267 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000910267 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000910267 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000910267 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000910267 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000910267 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000910267 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0000910267 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000910267 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0000910267 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000910267 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2019-04-01 2019-06-30 0000910267 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000910267 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2019-01-01 2019-03-31 0000910267 2019-01-01 2019-03-31 0000910267 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000910267 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2018-04-01 2018-06-30 0000910267 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000910267 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000910267 ttnp:AccumulatedDeficitsDuringDevelopmentStageMember 2018-01-01 2018-03-31 0000910267 2018-01-01 2018-03-31 0000910267 ttnp:HorizonLoanMember 2018-03-01 2018-03-31 0000910267 us-gaap:CommonStockMember us-gaap:SubsequentEventMember ttnp:SecuritiesPurchaseAgreementMember 2019-08-01 2019-08-31 0000910267 ttnp:ProductReturnsAllowanceMember 2019-01-01 2019-06-30 0000910267 ttnp:DiscountsAndRebatesAllowanceMember 2019-01-01 2019-06-30 0000910267 ttnp:ProductReturnsAllowanceMember 2019-06-30 0000910267 ttnp:DiscountsAndRebatesAllowanceMember 2019-06-30 0000910267 ttnp:ProductReturnsAllowanceMember 2018-12-31 0000910267 ttnp:DiscountsAndRebatesAllowanceMember 2018-12-31 0000910267 ttnp:HorizonTechnologyFinanceCorporationMember ttnp:VentureLoanMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2017-07-01 2017-07-31 0000910267 ttnp:HorizonTechnologyFinanceCorporationMember ttnp:VentureLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2017-07-01 2017-07-31 0000910267 ttnp:HorizonTechnologyFinanceCorporationMember ttnp:VentureLoanMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2017-07-01 2017-07-31 0000910267 2019-01-01 2019-01-31 0000910267 2019-04-01 2019-06-30 0000910267 2018-04-01 2018-06-30 0000910267 2018-01-01 2018-06-30 0000910267 ttnp:VentureLoanMember 2017-07-01 2017-07-27 0000910267 2019-06-30 0000910267 2018-12-31 0000910267 2019-08-10 0000910267 2019-01-01 2019-06-30 ttnp:segment ttnp:EquityInstruments iso4217:EUR iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares false --12-31 Q2 2019 2019-06-30 10-Q 0000910267 15741571 Yes false Non-accelerated Filer TITAN PHARMACEUTICALS INC false false TTNP 620000 504000 <div> <div> The Company We are a pharmaceutical company developing therapeutics for the treatment of select chronic diseases utilizing our proprietary long-term drug delivery platform, ProNeura™, and we are currently transitioning to a commercial stage enterprise having re-acquired Probuphine® in May 2018, our first product approved in the U.S. for the maintenance treatment of opioid dependence. We operate in only one business segment, the development and commercialization of pharmaceutical products. In January 2019, pursuant to prior stockholder authorization, our Board effected a reverse split of the outstanding shares of our common stock at a ratio of one share for every six shares then outstanding (the “Reverse Split”). Pursuant to their respective terms, the number of shares underlying our outstanding options and warrants was reduced and their respective exercise prices increased by the Reverse Split ratio. The number of shares of common stock authorized and the par value of $0.001 per share did not change as a result of the Reverse Split. All share and per share amounts contained in this Form 10‑Q give retroactive effect to the Reverse Split. <div /></div> </div> 99000 0.050 0.26 0.25 0.21 0.21 0 830000 1.55 0.04 0.02 0.03 81000 48000 33000 830000 71000 759000 -173000 -133000 -40000 922000 156000 766000 2852314 10000000

1526000

1025000

1737000

1140000

339397000

341708000

432000

402000

136000

350000

470000

834000

516000

318000

402000

246000

156000

486000

395000

91000

350000

336000

14000

843000

555000

288000

857000

610000

247000

1484000

333000

894000

257000

1734000

333000

1124000

277000

14095000

6761000

13301000

5493000

1614000

9295000

2292000

7883000

1975000

9656000

2292000

-5908000

-7364000

8900000

1600000

1.50

7.20

1.07

0.01

366668

6667

90000

2852314

1372314

0.001

125000000

13010000

14262000

13010000

14262000

13000

14000

<div> <div> The following table presents changes in contract assets and liabilities during the six months ended June 30, 2019 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Ending </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deductions </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contract assets </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (99) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contract liability: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (313) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

99000

830000

313000

550000

600000

70000

550000

246000

6778000

3307000

10614000

5384000

650000

649000

1000

448287

448000

650000

<div> <div> 5.    Debt Agreements Horizon and Molteni Loan In July 2017, we entered into a venture loan and security agreement that was subsequently amended in February 2018, (“Horizon Loan Agreement”) with Horizon Technology Finance Corporation (“Horizon”). Repayment of the loans is on an interest-only basis through December 31, 2019, followed by monthly payments of principal and accrued interest for the balance of the 46‑month term. The loans bear interest at a floating coupon rate of one-month LIBOR (floor of 1.10%) plus 8.40%. A final payment equal to 5.0% of each loan tranche will be due on the scheduled maturity date for such loan.  In addition, if we repay all or a portion of the loan prior to the applicable maturity date, we will pay Horizon a prepayment penalty fee, based on a percentage of the then outstanding principal balance, equal to 4% if the prepayment occurs during the interest-only payment period, 3% if the prepayment occurs during the 12 months following such period, and 2% thereafter. In connection with the Horizon Loan Agreement, we issued Horizon warrants that are currently exercisable to purchase an aggregate of 366,668 shares of our common stock at an exercise price per share of $1.50. In March 2018, we entered into an Amended and Restated Venture Loan and Security Agreement (the “Restated Loan Agreement”) with Horizon and Molteni pursuant to which Horizon assigned approximately $2.4 million of the $4.0 million outstanding principal balance of the loan to Molteni and Molteni was appointed as the collateral agent and assumed majority and administrative control of the loan. Under the Restated Loan Agreement, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $7.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $7.20 and repay the $1.6 million balance of Horizon’s loan amount. In connection with the Restated Loan Agreement, we issued warrants to purchase an aggregate of 6,667 shares of our common stock with an exercise price per share of $7.20 to Horizon. As of June 30, 2019, the loan from Molteni under the Restated Loan Agreement was convertible into 333,333 shares of our common stock. In consideration of Molteni’s entry into the Restated Loan Agreement and the Purchase Agreement, on March 21, 2018, we entered into a rights agreement (the “Rights Agreement”) with Molteni pursuant to which we agreed to (i) issue Molteni seven-year warrants to purchase 90,000 shares of our common stock at an exercise price of $7.20 per share (the “Molteni Warrants”), (ii) provide Molteni customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon conversion of its loan and exercise of the Molteni Warrants, (iii) designate one member of our board of directors following conversion of the loan in full and (iv) provide board observer rights to Molteni if it has not designated a board nominee as well as certain information rights. Molteni Convertible Loan In connection with the Amendment to the Molteni Purchase Agreement (see Note 4), in June 2019, the Molteni Convertible Loan, together with unpaid accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum,  was converted into 448,287 shares of our common stock at $1.50 per share upon the receipt of EMA approval of Sixmo. As a result, we recorded approximately $0.1 million of loss on debt extinguishment. There was no outstanding balance under the Molteni Convertible Loan as of June 30, 2019.   <div /></div> </div>

0.0840

0.0110

7.20

1.50

333333

1.10%

0.0950

1600000

P46M

313000

224000

123000

25000

<div> <div> 2.    Stock Plans In January 2019, our stockholders approved an amendment to the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan to increase the number of shares authorized for awards thereunder from 583,334 to 1,666,667. In January 2019, our stockholders approved a repricing of 122,115 fully-vested stock options with exercise prices in excess of $21.00 held by employees and consultants other than the named executive officers or members of the Board. The effected options were repriced at $1.55. As a result of the repricing of these stock options, we incurred a total of approximately $136,000 of additional stock-based compensation expense during the six months ended June 30, 2019, of which approximately $77,000 was recorded within research and development and approximately $59,000 within selling, general and administrative in our condensed statement of operations and comprehensive loss. The following table summarizes the stock-based compensation expense recorded for awards under our stock option plans (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 156 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 91 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 318 </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 336 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 246 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 395 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 516 </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 350 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 402 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 486 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 834 </td> </tr> </table></div>   We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the fair value of our stock options:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:15.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:15.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:15.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:15.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average risk-free interest rate </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.1 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.9 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.2 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.7 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend payments </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected holding period (years) 1 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  5.9 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6.4 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  5.4 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6.4 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted-average volatility factor 2 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.93 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.91 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.94 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.89 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Estimated forfeiture rates for options granted 3 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> </table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (2) </td><td style="width:0pt;"></td><td align="left" valign="top"> Weighted average volatility is based on the historical volatility of our common stock.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (3) </td><td style="width:0pt;"></td><td align="left" valign="top"> Estimated forfeiture rates are based on historical data.</td></tr></table></div> The following table summarizes option activity:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average  </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Option </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options (in </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price per </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (in </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value (in </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> thousands) </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> share </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> years) </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> thousands) </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at January 1, 2019 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 665 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17.94 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6.44 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4.0 </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 854 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.64 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (217) </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26.49 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding at June 30, 2019 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,302 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.82 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.47 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.8 </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable at June 30, 2019 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 669 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.83 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.23 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.1 </td> </tr> </table></div>   As of June 30, 2019, there was approximately $0.7 million of total unrecognized compensation expense related to non-vested stock options. This expense was expected to be recognized over a weighted-average period of approximately 1.75 years. <div /></div> </div>

-0.98

-0.25

-0.73

-0.38

<div> <div> 3.    Net Loss Per Share The table below presents common shares underlying stock options, warrants and convertible loans (see Note 5) that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average anti-dilutive common shares resulting from options </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,124 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 610 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 894 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 555 </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted-average anti-dilutive common shares resulting from warrants </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 277 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 247 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 257 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 288 </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average anti-dilutive common shares resulting from convertible loans </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 333 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 333 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,734 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 857 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,484 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 843 </td> </tr> </table></div>   <div /></div> </div>

700000

P1Y9M

-65000

-246000

-501000

124000

-597000

72000

-99000

939000

-313000

1317000

55000

232000

-155000

59000

197000

-428000

-230000

-499000

-253000

234000

219000

1262000

1317000

0.12

<div> <div> The following table presents maturities of our operating lease (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 (6 months) </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 153 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 308 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 155 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total minimum lease payments (base rent) </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 616 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: imputed interest </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (71) </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total operating lease liabilities </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 545 </td> </tr> </table></div>   <div /></div> </div>

616000

155000

308000

153000

71000

7264000

7332000

14095000

6761000

3452000

4342000

2400000

4000000

527000

1333000

3787000

2698000

-3000000

1176000

-53000

-83000

-2855000

-8457000

-2605000

-3474000

-869000

-4517000

-9714000

-5197000

-428000

-230000

-547000

-315000

-3046000

-639000

-9167000

-4882000

545000

253000

292000

514000

<div> <div> 1.     Organization and Summary of Significant Accounting Policies The Company We are a pharmaceutical company developing therapeutics for the treatment of select chronic diseases utilizing our proprietary long-term drug delivery platform, ProNeura™, and we are currently transitioning to a commercial stage enterprise having re-acquired Probuphine® in May 2018, our first product approved in the U.S. for the maintenance treatment of opioid dependence. We operate in only one business segment, the development and commercialization of pharmaceutical products. In January 2019, pursuant to prior stockholder authorization, our Board effected a reverse split of the outstanding shares of our common stock at a ratio of one share for every six shares then outstanding (the “Reverse Split”). Pursuant to their respective terms, the number of shares underlying our outstanding options and warrants was reduced and their respective exercise prices increased by the Reverse Split ratio. The number of shares of common stock authorized and the par value of $0.001 per share did not change as a result of the Reverse Split. All share and per share amounts contained in this Form 10‑Q give retroactive effect to the Reverse Split. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019, or any future interim periods. The balance sheet at December 31, 2018 is derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals, Inc. Annual Report on Form 10‑K/A for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (“SEC”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. The accompanying financial statements have been prepared assuming we will continue as a going concern. In August 2019, we received net proceeds of approximately $1.8 million for the sale of 2,852,314 shares of our common stock (and pre-funded warrants in lieu thereof) and warrants to purchase 2,852,314 shares of our common stock (see Note 7). As of June 30, 2019, we had cash and cash equivalents of approximately $2.3 million, which, we believe, together with the net proceeds from the August 2019 equity financing, is sufficient to fund our planned operations through October 2019. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful.   Going concern assessment We assess going concern uncertainty in our condensed financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the “look-forward period” as defined by Accounting Standard Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15. Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Quarterly Report on Form 10-Q for the six months ended June 30, 2019, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there is substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued. Use of Estimates The preparation of these unaudited condensed financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to warrants issued in equity financing, research and development expenses, income taxes, inventories, revenues, contingencies and litigation and share-based compensation. We base our estimates on historical experience, information received from third parties and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ significantly from those estimates under different assumptions or conditions. Revenue Recognition We generate revenue principally from the sale of Probuphine in the U.S., collaborative research and development arrangements, technology licenses and sales, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation. Net Product Revenue We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue is subject to a variety of deductions in the forms of variable consideration, which include rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration is estimated using the most-likely amount method, which is the single most-likely outcome under a contract and is typically at stated contractual rates. The actual outcome of this variable consideration may materially differ from our estimates. From time to time, we will adjust our estimates of this variable consideration when trends or significant events indicate that a change in estimate is appropriate to reflect the actual experience. Additionally, we will continue to assess the estimates of our variable consideration as we continue to accumulate additional historical data. Changes in the estimates of our variable consideration could materially affect our financial statements. Returns – Consistent with the provisions of ASC 606, we estimate returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which may impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.  During the six months ended June 30, 2019, we entered into agreements with large national specialty pharmacies with  a distribution channel different from that of our existing customers and, therefore, the related reserves have unique considerations. We will continue to evaluate the activities with these specialty pharmacies during upcoming quarters and will update the related reserves accordingly. Rebates – Our provision for rebates is estimated based on our customers’ contracted rebate programs and our historical experience of rebates paid. Discounts –The provision is estimated based upon invoice billings, utilizing historical customer payment experience. The following table provides a summary of activity with respect to our product returns, and discounts and rebates, which are included on our condensed consolidated balance sheets within accrued sales allowances (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Product </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Discounts and </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Returns </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Rebates </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Allowance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Allowance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 81 </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Provision </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 766 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 922 </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payments/credits </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (40) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (133) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (173) </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at June 30, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 759 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 830 </td> </tr> </table></div>   Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process. We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services. Transaction Price We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach. Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method. Research and Development Costs and Related Accrual Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (“CRO”) activities, sponsored research studies, product registration, patent application and prosecution, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Leases In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update, or ASU, No. 2016‑02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. We adopted the standard effective January 1, 2019. We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our condensed balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. We no longer recognize deferred rent on our condensed balance sheet. Recent Accounting Pronouncements Accounting Standards Adopted In February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842). Topic 842 requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. Effective January 1, 2019, we adopted the provisions under Topic 842 using a modified retrospective transition approach without adjusting comparative periods. Additionally, as permitted by Topic 842, we elected to apply the following practical expedients: (i) not to reassess whether any expired or existing contracts are or contain leases or the classification of any expired or existing leases and (ii) not to apply the recognition requirements to short-term leases. As a result of this adoption, we recorded operating lease right-of-use asset and operating lease liability associated with our office lease located on 400 Oyster Point Blvd., South San Francisco, California, in our condensed balance sheet as of March 31, 2019. We used a discount rate of 12%, which reflects our borrowing rate as of the adoption date, to measure the present value of future lease payments to determine the fair value of our operating lease right-of-use asset and liability. Our office lease expires in June 2021 and we did not include an estimated renewal in the calculation of our operating lease right-of-use asset and liability as we believe that it is less than probable we will renew our office lease. Our adoption of Topic 842 did not result in any cumulative adjustment to the balance of our accumulated deficit as of January 1, 2019. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term, which is consistent with Topic 840. The following table presents maturities of our operating lease (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 (6 months) </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 153 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 308 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 155 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total minimum lease payments (base rent) </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 616 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: imputed interest </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (71) </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total operating lease liabilities </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 545 </td> </tr> </table></div>   In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to nonemployees with the guidance applicable to grants to employees. Under the new standard, equity-classified share-based payment awards issued to nonemployees are measured on the grant date, instead of the current requirement to remeasure the awards through the performance completion date. We adopted ASU 2018-07 during the three months ended March 31, 2019 using the prospective approach. The adoption of ASU 2018-07 did not have any material impact to our condensed financial statements. In August 2018, the SEC published Release No. 33-10532, Disclosure Update and Simplification, or DUSTR, which adopted amendments to certain disclosure requirements that have become redundant, duplicative, overlapping, outdated or superseded, in light of other SEC disclosure requirements, GAAP, or changes in the information environment. While most of the DUSTR amendments eliminate updated or duplicative disclosure requirements, the final rule amends the interim financial statement requirements to include a reconciliation of changes in stockholders’ equity (deficit) in the notes or as a separate statement for each period for which a statement of comprehensive income (loss) is required to be filed. The new interim reconciliation of changes in stockholders’ equity (deficit) for the six months ended June 30, 2019 and 2018 is included herein. Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses, which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective for us in our interim period ending March 31, 2020. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We do not expect the adoption of this ASU to have any significant impact on our quarterly or annual disclosures. In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that Is a Service Contract. The ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Adoption of the ASU is either retrospective or prospective. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU No. 2018-15 on our condensed financial statements. Subsequent Events We have evaluated events that have occurred after June 30, 2019 and through the date that our condensed financial statements are issued. See Note 7. “Subsequent Events.” Fair Value Measurements Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, approximate their fair values due to the short-term nature of these instruments. Our investments in money market funds are classified within Level 1 of the fair value hierarchy. Our derivative liability is classified within level 3 of the fair value hierarchy because the fair value is calculated using significant judgment based on our own assumptions in the valuation of this liability. At June 30, 2019 and December 31, 2018, the fair value of our investments in money market funds were approximately $1.6 million and approximately $8.9 million, respectively, which are included within our cash and cash equivalents in our condensed balance sheets. <div /></div> </div>

466000

397000

208000

335000

17000

3000

-8000

53000

83000

547000

744000

466000

10000

1800000

2000000

2400000

710000

794000

754000

3000000

3713000

1857000

3751000

1907000

361000

-332579000

-342293000

3732000

3657000

75000

2000000

2300000

2668000

2593000

75000

950000

1100000

1447000

513000

313000

621000

502000

198000

304000

<div> <div> 4.    Molteni Purchase Agreement On March 21, 2018, we entered into a purchase agreement (“Molteni Purchase Agreement”) with L. Molteni & C. Dei Frattelli Alitti Società Di Esercizio S.P.A. (“Molteni”) pursuant to which Molteni acquired the European intellectual property related to Probuphine, including the marketing authorization application under review by the European Medicines Agency (“EMA”), and gained the exclusive right to commercialize the Probuphine product supplied by us in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa (the “Molteni Territory”). We received an initial payment of €2.0 million (approximately $2.4  million) for the purchased assets and will receive additional potential payments upon achievement of certain regulatory and product label milestones. Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory in percentages ranging from the low-teens to the mid-twenties. We concluded that the performance obligations identified in the Molteni Purchase Agreement included the transfer of the intellectual property and our efforts towards an approval by the EMA and other regulatory bodies. The initial payment was allocated between the property transfer and our EMA efforts as set forth below. We used the expected cost-plus approach to estimate the standalone selling price of approximately $1.4 million related to our efforts towards an approval by the EMA and other regulatory bodies (“Titan Services”). This includes employee related expenses as well as other manufacturing, regulatory and clinical costs, which are incurred as part of our efforts. As of March 31, 2019, we fully recognized the revenue associated with the Titan Services under the Molteni Purchase Agreement as we completed the Titan Services. The following table presents changes in contract assets and liabilities during the six months ended June 30, 2019 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Ending </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deductions </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contract assets </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 99 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (99) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Contract liability: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Deferred revenue </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 313 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (313) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   In August 2018, we entered into an amendment (the “Amendment”) to the Molteni Purchase Agreement. Under the Amendment, Molteni made an immediate payment of €950,000 (approximately $1.1 million) and a convertible loan of €550,000 (approximately $0.6 million) (“Molteni Convertible Loan”) (see Note 5) to us, both in exchange for the elimination of an aggregate of €2.0 million (approximately $2.3 million) of regulatory milestones provided for in the Molteni Purchase Agreement that are potentially payable in 2019, at the earliest. We concluded that the approximately $1.1 million immediate payment by Molteni reflected a milestone payment with no additional obligations to us and, therefore, was recognized as revenue during the year ended December 31, 2018. <div /></div> </div>

<div> <div> Revenue Recognition We generate revenue principally from the sale of Probuphine in the U.S., collaborative research and development arrangements, technology licenses and sales, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation. Net Product Revenue We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue is subject to a variety of deductions in the forms of variable consideration, which include rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration is estimated using the most-likely amount method, which is the single most-likely outcome under a contract and is typically at stated contractual rates. The actual outcome of this variable consideration may materially differ from our estimates. From time to time, we will adjust our estimates of this variable consideration when trends or significant events indicate that a change in estimate is appropriate to reflect the actual experience. Additionally, we will continue to assess the estimates of our variable consideration as we continue to accumulate additional historical data. Changes in the estimates of our variable consideration could materially affect our financial statements. Returns – Consistent with the provisions of ASC 606, we estimate returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which may impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement.  During the six months ended June 30, 2019, we entered into agreements with large national specialty pharmacies with  a distribution channel different from that of our existing customers and, therefore, the related reserves have unique considerations. We will continue to evaluate the activities with these specialty pharmacies during upcoming quarters and will update the related reserves accordingly. Rebates – Our provision for rebates is estimated based on our customers’ contracted rebate programs and our historical experience of rebates paid. Discounts –The provision is estimated based upon invoice billings, utilizing historical customer payment experience. The following table provides a summary of activity with respect to our product returns, and discounts and rebates, which are included on our condensed consolidated balance sheets within accrued sales allowances (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Product </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Discounts and </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Returns </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Rebates </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Allowance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Allowance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 81 </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Provision </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 766 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 922 </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payments/credits </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (40) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (133) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (173) </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at June 30, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 759 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 830 </td> </tr> </table></div>   Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process. We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services. Transaction Price We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach. Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method. <div /></div> </div>

1400000

P15Y

<div> <div> The following table provides a summary of activity with respect to our product returns, and discounts and rebates, which are included on our condensed consolidated balance sheets within accrued sales allowances (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Product </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Discounts and </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Returns </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Rebates </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Allowance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Allowance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 81 </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Provision </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 766 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 922 </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payments/credits </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (40) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (133) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (173) </td> </tr> <tr> <td valign="bottom" style="width:65.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance at June 30, 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 759 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 830 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> These are excluded from the calculation due to their anti-dilutive effect (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:17.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average anti-dilutive common shares resulting from options </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,124 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 610 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 894 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 555 </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted-average anti-dilutive common shares resulting from warrants </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 277 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 247 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 257 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 288 </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average anti-dilutive common shares resulting from convertible loans </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 333 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 333 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:61.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,734 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 857 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,484 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 843 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table summarizes the stock-based compensation expense recorded for awards under our stock option plans (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 156 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 91 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 318 </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 336 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 246 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 395 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 516 </td> </tr> <tr> <td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 350 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 402 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 486 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 834 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table summarizes option activity:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average  </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Option </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options (in </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price per </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (in </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value (in </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> thousands) </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> share </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> years) </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> thousands) </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at January 1, 2019 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 665 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17.94 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6.44 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4.0 </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 854 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.64 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cancelled </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (217) </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26.49 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding at June 30, 2019 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,302 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.82 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.47 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.8 </td> </tr> <tr> <td valign="bottom" style="width:41.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable at June 30, 2019 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 669 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.83 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.23 </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.1 </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:15.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:15.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:15.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:15.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average risk-free interest rate </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.1 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.9 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.2 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.7 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend payments </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected holding period (years) 1 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  5.9 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6.4 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  5.4 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6.4 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted-average volatility factor 2 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.93 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.91 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.94 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.89 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Estimated forfeiture rates for options granted 3 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:06.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 26 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> </table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (2) </td><td style="width:0pt;"></td><td align="left" valign="top"> Weighted average volatility is based on the historical volatility of our common stock.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (3) </td><td style="width:0pt;"></td><td align="left" valign="top"> Estimated forfeiture rates are based on historical data.</td></tr></table></div><div /></div> </div>

2995000

1380000

6313000

3231000

834000

486000

P6Y4M24D

P5Y4M24D

P5Y10M24D

0.0270

0.0290

0.0220

0.0210

0.0089

0.0091

0.0094

0.0093

583334

1666667

100

669000

9.83

P7Y2M23D

217000

854000

4000

800

665000

1302000

17.94

5.82

P6Y5M9D

P8Y5M19D

122115

136000

59000

77000

26.49

1.64

21.00

1.60

3534000

13010000

13414000

14262000

857000

-323271000

324124000

4000

-846000

-325876000

325026000

4000

-1313000

-326745000

325428000

4000

6831000

-332579000

339397000

13000

3055000

-337096000

340138000

13000

-571000

-342293000

341708000

14000

<div> <div> 6.    Stockholders’ Equity At-the-Market Offering (the “ATM”) In April 2019, we implemented the ATM for the sale of up to $8.6 million of our common stock. During the three months ended June 30, 2019, we issued a total of 329,656 shares of our common stock at a weighted-average price of $1.60 per share for total net proceeds of approximately $0.5 million under the ATM. In August 2019, in connection with the financing described in Note 7, we reduced the dollar amount that can be sold under ATM to $4.0 million.   <div /></div> </div>

0.1667

470000

329656

330000

1480000

404000

70000

8600000

466000

4000000

605000

105000

<div> <div> 7.    Subsequent Events In August 2019, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single accredited institutional investor (the “Purchaser”) pursuant to which we issued 1,480,000 shares of our common stock and pre-funded warrants to purchase 1,372,314 shares of our common stock with an exercise price of $0.01 per share (the “Pre-funded Warrants") in a registered direct offering and warrants to purchase 2,852,314 shares of our common stock with an exercise price of $1.07 per share (the “Placement Warrants") in a concurrent private placement. The Pre-Funded Warrants were issued in lieu of common stock in order to ensure the Purchaser did not exceed certain beneficial ownership limitations. The Placement Warrants will be exercisable commencing six months from the date of issuance and will expire five years following the initial exercise date. The terms of the Purchase Agreement include certain restrictions on our future stock offerings and granted to the Purchaser a participation right in future financings. We received net proceeds of approximately $1.8 million, after deduction of underwriting fees and other offering expenses.   <div /></div> </div>

Going concern assessmentWe assess going concern uncertainty in our condensed financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the "look-forward period" as defined by Accounting Standard Update ("ASU") No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Quarterly Report on Form 10-Q for the six months ended June 30, 2019, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there is substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.

3534000

13397000

13576000

Estimated forfeiture rates are based on historical data. Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior. Weighted average volatility is based on the historical volatility of our common stock. EX-101.SCH 5 ttnp-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Organization and Summary of Significant Accounting Policies - Summary of Maturities of Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Molteni Purchase Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Summary of Significant Accounting Policies - Summary of Activity Product Returns and Discounts and Rebates (Details) link:presentationLink link:calculationLink link:definitionLink 40103 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Stock Plans - Stock-based compensation expense recorded for awards (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Stock Plans - Fair value of stock options (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Stock Plans - Option activity (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Stock Plans - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Molteni Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Molteni Purchase Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Molteni Purchase Agreement - Additional Information Default (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Debt Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Stock Plans link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Molteni Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Debt Agreements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Stock Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ttnp-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 ttnp-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 ttnp-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Current Reporting Status Trading Symbol Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Shell Company Entity Small Business CONDENSED BALANCE SHEETS Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Restricted Cash Restricted cash Accounts Receivable, Net, Current Receivables Inventory, Net Inventory Contract with Customer, Asset, Gross Contract with Customer, Asset Contract assets Contract assets Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' (Deficit) Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Amount of accrued clinical trials expenses, current portion of the liabilities Accrued Clinical Trials Expenses, Current Accrued clinical trials expenses Product Warranty Accrual, Current Accrued sales allowances Other Accrued Liabilities, Current Other accrued liabilities Deferred Revenue, Current Deferred revenue Operating Lease, Liability, Current Operating lease liability, current Long-term Debt, Current Maturities Current portion of long-term debt Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Operating lease liability, non-current Long-term Debt, Excluding Current Maturities Long-term debt Derivative Liability, Noncurrent Derivative liability Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' (deficit) equity: Common Stock, Value, Issued Common stock, $0.001 par value per share: 125,000 shares authorized; 14,262 and 13,010 shares issued and outstanding at June 30, 2019 and December 31, 2018 Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' (deficit) equity Liabilities and Equity Total liabilities and stockholders' (deficit) equity Common Stock, Shares Authorized Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares, Issued Common stock shares, issued Common Stock, Shares, Outstanding Common Stock shares, Outstanding CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Revenues [Abstract] Revenues: Revenue from Contract with Customer, Including Assessed Tax Total revenues Costs and Expenses [Abstract] Operating expenses: Cost of Goods and Services Sold Cost of goods sold Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Costs and Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other expense: Interest Income (Expense), Nonoperating, Net Interest expense, net Gain (Loss) on Extinguishment of Debt Loss on debt extinguishment Other Nonoperating Income (Expense) Other income, net Nonoperating Income (Expense) Other expense, net Net Income (Loss) Attributable to Parent Net loss Net loss and comprehensive loss Net loss Earnings Per Share, Basic and Diluted Basic and diluted net loss per common share Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average shares used in computing basic and diluted net loss per common share CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Warrant Issued Issuance of warrants to purchase common stock, net Stock Issued During Period, Value, Other Issuance of common stock upon exercises of warrants, net Stock Issued During Period, Shares, Other Issuance of common stock upon exercises of warrants, net (in shares) Debt Conversion, Converted Instrument, Amount Issuance of common stock upon conversion of convertible loan Debt Conversion, Converted Instrument, Shares Issued Issuance of common stock upon conversion of convertible loan, (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock in at-the-market offerings, net Stock Issued During Period, Shares, New Issues Issuance of common stock in at-the-market offerings, net (in shares) Sale of common stock Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation CONDENSED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Other Noncash Expense Non-cash interest expense Share-based Compensation. Stock-based compensation Other Operating Income (Expense), Net Other Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Receivables Increase (Decrease) in Inventories Inventory Increase (Decrease) in Contract with Customer, Asset Contract assets Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable The increase (decrease) during the reporting period in accrued sales allowances. Increase (Decrease) in Accrued Sales Allowances Accrued sales allowances Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Other accrued liabilities Increase (Decrease) in Contract with Customer, Liability Deferred revenue Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Warrant Exercises Net proceeds from the exercises of common stock warrants Proceeds from Issuance of Common Stock Net proceeds from the issuance of common stock in an at-the-market offering Proceeds from sale of common stock Repayments of Long-term Debt Payments of long-term debt Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash shown in the statement of cash flows Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Interest paid Stock Issued Warrants issued Debt Conversion, Original Debt, Amount Non-cash conversion of Molteni Convertible Loan Noncash Investing and Financing Items [Abstract] Schedule of non-cash transactions Restricted Cash and Cash Equivalents Restricted cash Organization and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Organization and Summary of Significant Policies Stock Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Plans Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Purchase Agreement abstract Molteni Purchase Agreement Revenue from Contract with Customer [Text Block] Molteni Purchase Agreement Debt Agreements Debt Disclosure [Text Block] Debt Agreements Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Subsequent Events Subsequent Events [Text Block] Subsequent Events The company. Company Policy [Policy Text Block] The Company Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Research and Development Expense, Policy [Policy Text Block] Research and Development Costs and Related Accrual Lessee, Leases [Policy Text Block] Leases New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Subsequent Events, Policy [Policy Text Block] Subsequent Events Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Summary of activity with respect to our product returns, and discounts and rebates Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of maturities of operating lease Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation expense recorded for awards under our stock option plans Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of estimate the fair value of stock options Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of option activity Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Purchase Agreement Table Purchase Agreement [Table] Purchase Agreement Lineitem Purchase Agreement [Line Items] Purchase Agreement Contract with Customer, Asset and Liability [Table Text Block] Schedule of changes in contract assets and liabilities XXX_Allowance Axis Allowance [Axis] XXX_Allowance Axis Allowance [Domain] Allowance [Domain] XXX_Product Returns Allowance Member Product Returns Allowance [Member] Product Returns Allowance [Member] XXX_Discounts And Rebates Allowance Member Discounts And Rebates Allowance [Member] Discounts and Rebates Allowance [Member] The amount represents reserve for sales returns. Revenue Recognition ReserveFor Sales Returns Balance at June 30, 2019 Balance at December 31, 2018 Amount of estimated provision of sales returns. Revenue Recognition Sales Returns Provision For Sales Returns Provision The amount represents payment of sales returns. Revenue Recognition Sale Returns Payments/credits Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2019 (6 months) Lessee, Operating Lease, Liability, Payments, Due Year Two 2020 Lessee, Operating Lease, Liability, Payments, Due Year Three 2021 Lessee, Operating Lease, Liability, Payments, Due Total minimum lease payments (base rent) Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Operating Lease, Liability Total operating lease liabilities Organization and summary of significant accounting policies. Schedule of Organization and Summary of Significant Accounting Policies [Table] Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Fair Value, Recurring [Member] Cash and Cash Equivalents [Axis] Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Cash and Cash Equivalents [Domain] Money Market Funds [Member] Money Market Funds [Member] Adjustments for New Accounting Pronouncements [Axis] Type Of Adoption [Member] Type of Adoption [Domain] Accounting Standards Update201602 [Member] Accounting Standards Update 2016-02 [Member] Schedule of organization and summary of significant accounting policies. Schedule of Organization and Summary of Significant Accounting Policies [Line Items] Schedule of Organization and Summary of Significant Accounting Policies Number of Operating Segments Stockholders' Equity Note, Stock Split, Conversion Ratio Substantial Doubt about Going Concern, Management's Evaluation Lessee, Operating Lease, Discount Rate Number of new stock and warrants issued during the period. Stock and Warrants Issued During Period, New Issues Class of Warrant or Right, Number of Securities Called by Warrants or Rights Cash Equivalents, at Carrying Value Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research And Development Expense [Member] Research and development General And Administrative Expense [Member] General and administrative Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Allocated Share-based Compensation Expense Total stock-based compensation expense Schedule of Share-based Goods and Nonemployee Services Transaction [Table] Share-based Goods and Nonemployee Services Transaction [Line Items] Share-based Goods and Nonemployee Services Transaction Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted-average risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments Expected dividend payments Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected holding period (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Weighted-average volatility factor Estimated forfeiture rates for options granted to management. Estimated Forfeiture Rates for Options Granted to Management Estimated forfeiture rates for options granted Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Options and Awards Outstanding at End of Period Number of Options and Awards Outstanding at Beginning of Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Shares, Granted EX-101.PRE 9 ttnp-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 10, 2019
Document and Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Registrant Name	TITAN PHARMACEUTICALS INC
Entity Central Index Key	0000910267
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	TTNP
Entity Common Stock, Shares Outstanding		15,741,571
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Small Business	false

XML 11 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,292	$ 9,295
Restricted cash	0	361
Receivables	1,140	1,737
Inventory	1,317	1,262
Contract assets	0	99
Prepaid expenses and other current assets	744	547
Total current assets	5,493	13,301
Property and equipment, net	754	794
Operating lease right-of-use asset	514	0
Total assets	6,761	14,095
Current liabilities:
Accounts payable	1,025	1,526
Accrued clinical trials expenses	504	620
Accrued sales allowances	830	0
Other accrued liabilities	397	466
Deferred revenue	0	313
Operating lease liability, current	253	0
Current portion of long-term debt	1,333	527
Total current liabilities	4,342	3,452
Operating lease liability, non-current	292	0
Long-term debt	2,698	3,787
Derivative liability	0	25
Total liabilities	7,332	7,264
Stockholders' (deficit) equity:
Common stock, $0.001 par value per share: 125,000 shares authorized; 14,262 and 13,010 shares issued and outstanding at June 30, 2019 and December 31, 2018	14	13
Additional paid-in capital	341,708	339,397
Accumulated deficit	(342,293)	(332,579)
Total stockholders' (deficit) equity	(571)	6,831
Total liabilities and stockholders' (deficit) equity	$ 6,761	$ 14,095

XML 12 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Jun. 30, 2019	Dec. 31, 2018
CONDENSED BALANCE SHEETS
Common Stock, Shares Authorized	125,000	125,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock shares, issued	14,262	13,010
Common Stock shares, Outstanding	14,262	13,010

XML 13 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares
Revenues:
Total revenues	$ 502	$ 2,668	$ 1,447	$ 3,732
Operating expenses:
Cost of goods sold	246	70	550	70
Research and development	1,907	1,857	3,751	3,713
Selling, general and administrative	3,231	1,380	6,313	2,995
Total operating expenses	5,384	3,307	10,614	6,778
Loss from operations	(4,882)	(639)	(9,167)	(3,046)
Other expense:
Interest expense, net	(253)	(230)	(499)	(428)
Loss on debt extinguishment	(65)	0	(65)	0
Other income, net	3	0	17	0
Other expense, net	(315)	(230)	(547)	(428)
Net loss and comprehensive loss	$ (5,197)	$ (869)	$ (9,714)	$ (3,474)
Basic and diluted net loss per common share \| $ / shares	$ (0.38)	$ (0.25)	$ (0.73)	$ (0.98)
Weighted average shares used in computing basic and diluted net loss per common share \| shares	13,576	3,534	13,397	3,534
License revenue
Revenues:
Total revenues	$ 0	$ 2,593	$ 313	$ 3,657
Product revenue
Revenues:
Total revenues	304	75	621	75
Grant revenue
Revenues:
Total revenues	$ 198	$ 0	$ 513	$ 0

XML 14 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 4	$ 324,124	$ (323,271)	$ 857
Balance (in shares) at Dec. 31, 2017	3,534
Net loss	$ 0	0	(2,605)	(2,605)
Issuance of warrants to purchase common stock, net	0	470	0	470
Stock-based compensation	0	432	0	432
Balance at Mar. 31, 2018	$ 4	325,026	(325,876)	(846)
Balance (in shares) at Mar. 31, 2018	3,534
Balance at Dec. 31, 2017	$ 4	324,124	(323,271)	857
Balance (in shares) at Dec. 31, 2017	3,534
Net loss				(3,474)
Balance at Jun. 30, 2018	$ 4	325,428	(326,745)	(1,313)
Balance (in shares) at Jun. 30, 2018	3,534
Balance at Mar. 31, 2018	$ 4	325,026	(325,876)	(846)
Balance (in shares) at Mar. 31, 2018	3,534
Net loss	$ 0	0	(869)	(869)
Stock-based compensation	0	402	0	402
Balance at Jun. 30, 2018	$ 4	325,428	(326,745)	(1,313)
Balance (in shares) at Jun. 30, 2018	3,534
Balance at Dec. 31, 2018	$ 13	339,397	(332,579)	6,831
Balance (in shares) at Dec. 31, 2018	13,010
Net loss	$ 0	0	(4,517)	(4,517)
Issuance of common stock upon exercises of warrants, net	$ 0	605	0	605
Issuance of common stock upon exercises of warrants, net (in shares)	404
Stock-based compensation	$ 0	136	0	136
Balance at Mar. 31, 2019	$ 13	340,138	(337,096)	3,055
Balance (in shares) at Mar. 31, 2019	13,414
Balance at Dec. 31, 2018	$ 13	339,397	(332,579)	6,831
Balance (in shares) at Dec. 31, 2018	13,010
Net loss				(9,714)
Balance at Jun. 30, 2019	$ 14	341,708	(342,293)	(571)
Balance (in shares) at Jun. 30, 2019	14,262
Balance at Mar. 31, 2019	$ 13	340,138	(337,096)	3,055
Balance (in shares) at Mar. 31, 2019	13,414
Net loss	$ 0	0	(5,197)	(5,197)
Issuance of common stock upon exercises of warrants, net	$ 0	105	0	105
Issuance of common stock upon exercises of warrants, net (in shares)	70
Issuance of common stock upon conversion of convertible loan	$ 1	649	0	650
Issuance of common stock upon conversion of convertible loan, (in shares)	448
Issuance of common stock in at-the-market offerings, net	$ 0	466	0	466
Issuance of common stock in at-the-market offerings, net (in shares)	330
Stock-based compensation	$ 0	350	0	350
Balance at Jun. 30, 2019	$ 14	$ 341,708	$ (342,293)	$ (571)
Balance (in shares) at Jun. 30, 2019	14,262

XML 15 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (9,714)	$ (3,474)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization	123	224
Non-cash interest expense	335	208
Stock-based compensation	486	834
Other	8	0
Changes in operating assets and liabilities:
Receivables	597	(124)
Inventory	(55)	(1,317)
Contract assets	99	(72)
Prepaid expenses and other assets	(197)	(59)
Accounts payable	(501)	(246)
Accrued sales allowances	830	0
Other accrued liabilities	(155)	232
Deferred revenue	(313)	939
Net cash used in operating activities	(8,457)	(2,855)
Cash flows from investing activities:
Purchases of property and equipment	(83)	(53)
Net cash used in investing activities	(83)	(53)
Cash flows from financing activities:
Net proceeds from the exercises of common stock warrants	710	0
Net proceeds from the issuance of common stock in an at-the-market offering	466	0
Payments of long-term debt	0	(3,000)
Net cash provided by (used in) financing activities	1,176	(3,000)
Net decrease in cash and cash equivalents	(7,364)	(5,908)
Cash, cash equivalents and restricted cash at beginning of period	9,656	7,883
Cash, cash equivalents and restricted cash at end of period	2,292	1,975
Supplemental disclosure of cash flow information:
Interest paid	219	234
Warrants issued	0	470
Non-cash conversion of Molteni Convertible Loan	650	0
Schedule of non-cash transactions
Restricted cash	0	361
Cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 9,656	$ 7,883

XML 16 R7.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Organization and Summary of Significant Accounting Policies

Organization and Summary of Significant Policies

1. Organization and Summary of Significant Accounting Policies

The Company

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019, or any future interim periods.

The balance sheet at December 31, 2018 is derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals, Inc. Annual Report on Form 10‑K/A for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (“SEC”).

Going concern assessment

Use of Estimates

Revenue Recognition

Net Product Revenue

Rebates – Our provision for rebates is estimated based on our customers’ contracted rebate programs and our historical experience of rebates paid.

Discounts –The provision is estimated based upon invoice billings, utilizing historical customer payment experience.


	Product		Discounts and
	Returns		Rebates
	Allowance		Allowance		Total
Balance at December 31, 2018	$	33	$	48	$	81
Provision		766		156		922
Payments/credits		(40)		(133)		(173)
Balance at June 30, 2019	$	759	$	71	$	830

Performance Obligations

Transaction Price

Allocation of Consideration

Timing of Recognition

Research and Development Costs and Related Accrual

Leases

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update, or ASU, No. 2016‑02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. We adopted the standard effective January 1, 2019.

Recent Accounting Pronouncements

Accounting Standards Adopted

In February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842). Topic 842 requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. Effective January 1, 2019, we adopted the provisions under Topic 842 using a modified retrospective transition approach without adjusting comparative periods. Additionally, as permitted by Topic 842, we elected to apply the following practical expedients: (i) not to reassess whether any expired or existing contracts are or contain leases or the classification of any expired or existing leases and (ii) not to apply the recognition requirements to short-term leases. As a result of this adoption, we recorded operating lease right-of-use asset and operating lease liability associated with our office lease located on 400 Oyster Point Blvd., South San Francisco, California, in our condensed balance sheet as of March 31, 2019. We used a discount rate of 12%, which reflects our borrowing rate as of the adoption date, to measure the present value of future lease payments to determine the fair value of our operating lease right-of-use asset and liability. Our office lease expires in June 2021 and we did not include an estimated renewal in the calculation of our operating lease right-of-use asset and liability as we believe that it is less than probable we will renew our office lease. Our adoption of Topic 842 did not result in any cumulative adjustment to the balance of our accumulated deficit as of January 1, 2019. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term, which is consistent with Topic 840.

The following table presents maturities of our operating lease (in thousands):


2019 (6 months)	$	153
2020		308
2021		155
Total minimum lease payments (base rent)		616
Less: imputed interest		(71)
Total operating lease liabilities	$	545

Accounting Standards Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses, which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective for us in our interim period ending March 31, 2020. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We do not expect the adoption of this ASU to have any significant impact on our quarterly or annual disclosures.

In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that Is a Service Contract. The ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Adoption of the ASU is either retrospective or prospective. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU No. 2018-15 on our condensed financial statements.

Subsequent Events

We have evaluated events that have occurred after June 30, 2019 and through the date that our condensed financial statements are issued. See Note 7. “Subsequent Events.”

Fair Value Measurements

XML 17 R8.htm IDEA: XBRL DOCUMENT

Stock Plans

6 Months Ended

Jun. 30, 2019

Stock Plans

Stock Plans

2. Stock Plans

The following table summarizes the stock-based compensation expense recorded for awards under our stock option plans (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Research and development	$	14	$	156	$	91	$	318
Selling, general and administrative		336		246		395		516
Total stock-based compensation	$	350	$	402	$	486	$	834

We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the fair value of our stock options:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Weighted-average risk-free interest rate	2.1	%	2.9	%	2.2	%	2.7	%
Expected dividend payments	—		—		—		—
Expected holding period (years) 1	5.9		6.4		5.4		6.4
Weighted-average volatility factor 2	0.93		0.91		0.94		0.89
Estimated forfeiture rates for options granted 3	21	%	25	%	21	%	26	%

(1)

(2)

Weighted average volatility is based on the historical volatility of our common stock.

(3)

Estimated forfeiture rates are based on historical data.

The following table summarizes option activity:


				Weighted
		Weighted		Average
		Average		Remaining	Aggregate
		Exercise		Option	Intrinsic
	Options (in	Price per		Term (in	Value (in
	thousands)	share		years)	thousands)
Outstanding at January 1, 2019	665	$	17.94	6.44	$	4.0
Granted	854		1.64
Cancelled	(217)		26.49
Outstanding at June 30, 2019	1,302		5.82	8.47		0.8
Exercisable at June 30, 2019	669		9.83	7.23		0.1

XML 18 R9.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

6 Months Ended

Jun. 30, 2019

Net Loss Per Share

Net Loss Per Share

3. Net Loss Per Share


	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2019	2018	2019	2018
Weighted-average anti-dilutive common shares resulting from options	1,124	610	894	555
Weighted-average anti-dilutive common shares resulting from warrants	277	247	257	288
Weighted-average anti-dilutive common shares resulting from convertible loans	333	—	333	—
	1,734	857	1,484	843

XML 19 R10.htm IDEA: XBRL DOCUMENT

Molteni Purchase Agreement

6 Months Ended

Jun. 30, 2019

Molteni Purchase Agreement

Molteni Purchase Agreement

4. Molteni Purchase Agreement

The following table presents changes in contract assets and liabilities during the six months ended June 30, 2019 (in thousands):


	Beginning				Ending
(in thousands)	Balance		Deductions		Balance
Contract assets	$	99	$	(99)	$	—
Contract liability:
Deferred revenue	$	313	$	(313)	$	—

XML 20 R11.htm IDEA: XBRL DOCUMENT

Debt Agreements	6 Months Ended
Debt Agreements	Jun. 30, 2019
Debt Agreements
Debt Agreements	5. Debt Agreements Horizon and Molteni Loan In July 2017, we entered into a venture loan and security agreement that was subsequently amended in February 2018, (“Horizon Loan Agreement”) with Horizon Technology Finance Corporation (“Horizon”). Repayment of the loans is on an interest-only basis through December 31, 2019, followed by monthly payments of principal and accrued interest for the balance of the 46‑month term. The loans bear interest at a floating coupon rate of one-month LIBOR (floor of 1.10%) plus 8.40%. A final payment equal to 5.0% of each loan tranche will be due on the scheduled maturity date for such loan. In addition, if we repay all or a portion of the loan prior to the applicable maturity date, we will pay Horizon a prepayment penalty fee, based on a percentage of the then outstanding principal balance, equal to 4% if the prepayment occurs during the interest-only payment period, 3% if the prepayment occurs during the 12 months following such period, and 2% thereafter. In connection with the Horizon Loan Agreement, we issued Horizon warrants that are currently exercisable to purchase an aggregate of 366,668 shares of our common stock at an exercise price per share of $1.50. In March 2018, we entered into an Amended and Restated Venture Loan and Security Agreement (the “Restated Loan Agreement”) with Horizon and Molteni pursuant to which Horizon assigned approximately $2.4 million of the $4.0 million outstanding principal balance of the loan to Molteni and Molteni was appointed as the collateral agent and assumed majority and administrative control of the loan. Under the Restated Loan Agreement, Molteni has the right to convert its portion of the debt into shares of our common stock at a conversion price of $7.20 per share and is required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $7.20 and repay the $1.6 million balance of Horizon’s loan amount. In connection with the Restated Loan Agreement, we issued warrants to purchase an aggregate of 6,667 shares of our common stock with an exercise price per share of $7.20 to Horizon. As of June 30, 2019, the loan from Molteni under the Restated Loan Agreement was convertible into 333,333 shares of our common stock. In consideration of Molteni’s entry into the Restated Loan Agreement and the Purchase Agreement, on March 21, 2018, we entered into a rights agreement (the “Rights Agreement”) with Molteni pursuant to which we agreed to (i) issue Molteni seven-year warrants to purchase 90,000 shares of our common stock at an exercise price of $7.20 per share (the “Molteni Warrants”), (ii) provide Molteni customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon conversion of its loan and exercise of the Molteni Warrants, (iii) designate one member of our board of directors following conversion of the loan in full and (iv) provide board observer rights to Molteni if it has not designated a board nominee as well as certain information rights. Molteni Convertible Loan In connection with the Amendment to the Molteni Purchase Agreement (see Note 4), in June 2019, the Molteni Convertible Loan, together with unpaid accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum, was converted into 448,287 shares of our common stock at $1.50 per share upon the receipt of EMA approval of Sixmo. As a result, we recorded approximately $0.1 million of loss on debt extinguishment. There was no outstanding balance under the Molteni Convertible Loan as of June 30, 2019.

XML 21 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2019
Stockholders' Equity
Stockholders' Equity	6. Stockholders’ Equity At-the-Market Offering (the “ATM”) In April 2019, we implemented the ATM for the sale of up to $8.6 million of our common stock. During the three months ended June 30, 2019, we issued a total of 329,656 shares of our common stock at a weighted-average price of $1.60 per share for total net proceeds of approximately $0.5 million under the ATM. In August 2019, in connection with the financing described in Note 7, we reduced the dollar amount that can be sold under ATM to $4.0 million.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2019
Subsequent Events
Subsequent Events	7. Subsequent Events In August 2019, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single accredited institutional investor (the “Purchaser”) pursuant to which we issued 1,480,000 shares of our common stock and pre-funded warrants to purchase 1,372,314 shares of our common stock with an exercise price of $0.01 per share (the “Pre-funded Warrants") in a registered direct offering and warrants to purchase 2,852,314 shares of our common stock with an exercise price of $1.07 per share (the “Placement Warrants") in a concurrent private placement. The Pre-Funded Warrants were issued in lieu of common stock in order to ensure the Purchaser did not exceed certain beneficial ownership limitations. The Placement Warrants will be exercisable commencing six months from the date of issuance and will expire five years following the initial exercise date. The terms of the Purchase Agreement include certain restrictions on our future stock offerings and granted to the Purchaser a participation right in future financings. We received net proceeds of approximately $1.8 million, after deduction of underwriting fees and other offering expenses.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Organization and Summary of Significant Accounting Policies

The Company

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019, or any future interim periods.

The balance sheet at December 31, 2018 is derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals, Inc. Annual Report on Form 10‑K/A for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (“SEC”).

Use of Estimates

Revenue Recognition

Net Product Revenue

Rebates – Our provision for rebates is estimated based on our customers’ contracted rebate programs and our historical experience of rebates paid.

Discounts –The provision is estimated based upon invoice billings, utilizing historical customer payment experience.


	Product		Discounts and
	Returns		Rebates
	Allowance		Allowance		Total
Balance at December 31, 2018	$	33	$	48	$	81
Provision		766		156		922
Payments/credits		(40)		(133)		(173)
Balance at June 30, 2019	$	759	$	71	$	830

Performance Obligations

Transaction Price

Allocation of Consideration

Timing of Recognition

Research and Development Costs and Related Accrual

Leases

Recent Accounting Pronouncements

Accounting Standards Adopted

The following table presents maturities of our operating lease (in thousands):


2019 (6 months)	$	153
2020		308
2021		155
Total minimum lease payments (base rent)		616
Less: imputed interest		(71)
Total operating lease liabilities	$	545

Accounting Standards Not Yet Adopted

Subsequent Events

We have evaluated events that have occurred after June 30, 2019 and through the date that our condensed financial statements are issued. See Note 7. “Subsequent Events.”

XML 24 R15.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Organization and Summary of Significant Accounting Policies

Summary of activity with respect to our product returns, and discounts and rebates


	Product		Discounts and
	Returns		Rebates
	Allowance		Allowance		Total
Balance at December 31, 2018	$	33	$	48	$	81
Provision		766		156		922
Payments/credits		(40)		(133)		(173)
Balance at June 30, 2019	$	759	$	71	$	830

Schedule of maturities of operating lease

The following table presents maturities of our operating lease (in thousands):


2019 (6 months)	$	153
2020		308
2021		155
Total minimum lease payments (base rent)		616
Less: imputed interest		(71)
Total operating lease liabilities	$	545

XML 25 R16.htm IDEA: XBRL DOCUMENT

Stock Plans (Tables)

6 Months Ended

Jun. 30, 2019

Stock Plans

Schedule of stock-based compensation expense recorded for awards under our stock option plans

The following table summarizes the stock-based compensation expense recorded for awards under our stock option plans (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Research and development	$	14	$	156	$	91	$	318
Selling, general and administrative		336		246		395		516
Total stock-based compensation	$	350	$	402	$	486	$	834

Schedule of estimate the fair value of stock options


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Weighted-average risk-free interest rate	2.1	%	2.9	%	2.2	%	2.7	%
Expected dividend payments	—		—		—		—
Expected holding period (years) 1	5.9		6.4		5.4		6.4
Weighted-average volatility factor 2	0.93		0.91		0.94		0.89
Estimated forfeiture rates for options granted 3	21	%	25	%	21	%	26	%

(1)

(2)

Weighted average volatility is based on the historical volatility of our common stock.

(3)

Estimated forfeiture rates are based on historical data.

Schedule of option activity

The following table summarizes option activity:


				Weighted
		Weighted		Average
		Average		Remaining	Aggregate
		Exercise		Option	Intrinsic
	Options (in	Price per		Term (in	Value (in
	thousands)	share		years)	thousands)
Outstanding at January 1, 2019	665	$	17.94	6.44	$	4.0
Granted	854		1.64
Cancelled	(217)		26.49
Outstanding at June 30, 2019	1,302		5.82	8.47		0.8
Exercisable at June 30, 2019	669		9.83	7.23		0.1

XML 26 R17.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2019

Net Loss Per Share

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

These are excluded from the calculation due to their anti-dilutive effect (in thousands):


	Three Months Ended		Six Months Ended
	June 30,		June 30,
	2019	2018	2019	2018
Weighted-average anti-dilutive common shares resulting from options	1,124	610	894	555
Weighted-average anti-dilutive common shares resulting from warrants	277	247	257	288
Weighted-average anti-dilutive common shares resulting from convertible loans	333	—	333	—
	1,734	857	1,484	843

XML 27 R18.htm IDEA: XBRL DOCUMENT

Molteni Purchase Agreement (Tables)

6 Months Ended

Jun. 30, 2019

Molteni Purchase Agreement

Schedule of changes in contract assets and liabilities

The following table presents changes in contract assets and liabilities during the six months ended June 30, 2019 (in thousands):


	Beginning				Ending
(in thousands)	Balance		Deductions		Balance
Contract assets	$	99	$	(99)	$	—
Contract liability:
Deferred revenue	$	313	$	(313)	$	—

XML 28 R19.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Summary of Activity Product Returns and Discounts and Rebates (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Balance at December 31, 2018	$ 81
Provision	922
Payments/credits	(173)
Balance at June 30, 2019	830
Product Returns Allowance [Member]
Balance at December 31, 2018	33
Provision	766
Payments/credits	(40)
Balance at June 30, 2019	759
Discounts and Rebates Allowance [Member]
Balance at December 31, 2018	48
Provision	156
Payments/credits	(133)
Balance at June 30, 2019	$ 71

XML 29 R20.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Summary of Maturities of Operating Lease (Details) $ in Thousands	Jun. 30, 2019 USD ($)
Organization and Summary of Significant Accounting Policies
2019 (6 months)	$ 153
2020	308
2021	155
Total minimum lease payments (base rent)	616
Less: imputed interest	(71)
Total operating lease liabilities	$ 545

XML 30 R21.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Additional Information (Details)	1 Months Ended			3 Months Ended	6 Months Ended
	Aug. 31, 2019 USD ($) shares	Jul. 31, 2019 USD ($)	Jan. 31, 2019 $ / shares	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) segment $ / shares	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) $ / shares
Schedule of Organization and Summary of Significant Accounting Policies
Number of Operating Segments \| segment					1
Stockholders' Equity Note, Stock Split, Conversion Ratio			0.1667
Substantial Doubt about Going Concern, Management's Evaluation						Going concern assessmentWe assess going concern uncertainty in our condensed financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the "look-forward period" as defined by Accounting Standard Update ("ASU") No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.Based upon the above assessment, we concluded that, at the date of filing the financial statements in this Quarterly Report on Form 10-Q for the six months ended June 30, 2019, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there is substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.
Cash and Cash Equivalents, at Carrying Value				$ 2,292,000	$ 2,292,000	$ 1,614,000	$ 9,295,000
Common Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001	$ 0.001	$ 0.001		$ 0.001
Proceeds from sale of common stock					$ 466,000	$ 0
Subsequent Event
Schedule of Organization and Summary of Significant Accounting Policies
Proceeds from sale of common stock		$ 10,000
Accounting Standards Update 2016-02 [Member]
Schedule of Organization and Summary of Significant Accounting Policies
Lessee, Operating Lease, Discount Rate			12.00%
Fair Value, Recurring [Member] \| Money Market Funds [Member]
Schedule of Organization and Summary of Significant Accounting Policies
Cash Equivalents, at Carrying Value				$ 1,600,000	$ 1,600,000		$ 8,900,000
Common Stock [Member]
Schedule of Organization and Summary of Significant Accounting Policies
Sale of common stock \| shares				330,000
Purchase Agreement [Member] \| Common Stock [Member] \| Subsequent Event
Schedule of Organization and Summary of Significant Accounting Policies
Proceeds from sale of common stock	$ 1,800,000
Stock and Warrants Issued During Period, New Issues \| shares	2,852,314
Sale of common stock \| shares	1,480,000
Purchase Agreement [Member] \| Common Stock [Member] \| Placement Warrants [Member] \| Subsequent Event
Schedule of Organization and Summary of Significant Accounting Policies
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	2,852,314

XML 31 R22.htm IDEA: XBRL DOCUMENT

Stock Plans - Stock-based compensation expense recorded for awards (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Total stock-based compensation expense	$ 350	$ 402	$ 486	$ 834
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Total stock-based compensation expense	14	156	91	318
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Total stock-based compensation expense	$ 336	$ 246	$ 395	$ 516

XML 32 R23.htm IDEA: XBRL DOCUMENT

Stock Plans - Fair value of stock options (Details) - USD ($)

3 Months Ended

6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Stock Plans

Weighted-average risk-free interest rate

2.10%

2.90%

2.20%

2.70%

Expected dividend payments

$ 0

Expected holding period (years)

5 years 10 months 24 days

^[1]

6 years 4 months 24 days

^[1]

5 years 4 months 24 days

6 years 4 months 24 days

Weighted-average volatility factor

0.93%

^[2]

0.91%

^[2]

0.94%

0.89%

Estimated forfeiture rates for options granted

21.00%

^[3]

25.00%

^[3]

21.00%

26.00%

[1]	Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.
[2]	Weighted average volatility is based on the historical volatility of our common stock.
[3]	Estimated forfeiture rates are based on historical data.

XML 33 R24.htm IDEA: XBRL DOCUMENT

Stock Plans - Option activity (Details) - USD ($) $ / shares in Units, shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Stock Plans
Number of Options and Awards Outstanding at Beginning of Period	665
Shares, Granted	854
Shares, Cancelled	(217)
Number of Options and Awards Outstanding at End of Period	1,302	665
Shares, Exercisable at June 30, 2019	669
Weighted Average Exercise Price, Outstanding at Beginning of Period	$ 17.94
Weighted Average Exercise Price, Granted	1.64
Weighted Average Exercise Price, Cancelled	26.49
Weighted Average Exercise Price, Outstanding at End of Period	5.82	$ 17.94
Weighted Average Exercise Price, Exercisable at June 30, 2019	$ 9.83
Weighted Average Remaining Contractual Term, Outstanding (Years)	8 years 5 months 19 days	6 years 5 months 9 days
Weighted Average Remaining Contractual Term, Exercisable at December 31, 2018	7 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding at Beginning of Period	$ 4,000
Aggregate Intrinsic Value, Outstanding at End of Period	800	$ 4,000
Aggregate Intrinsic Value, Exercisable at December 31, 2017	$ 100

XML 34 R25.htm IDEA: XBRL DOCUMENT

Stock Plans - Additional Information (Details) - USD ($)	1 Months Ended	6 Months Ended
	Jan. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award
Weighted-average period for recognizing non-vested stock option		1 year 9 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	122,115
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 21.00
Increase In The Price In Respect Of Lower Range In Respect Of Shares Authorised Under Compensation Plan	$ 1.55
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 700,000
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,666,667		583,334
Stock Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		136,000
Stock Compensation Plan \| Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		77,000
Stock Compensation Plan \| General and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		$ 59,000

XML 35 R26.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
Net Loss Per Share (Details) - shares shares in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,734	857	1,484	843
Convertible Debt Securities
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	333	0	333
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,124	610	894	555
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	277	247	257	288

XML 36 R27.htm IDEA: XBRL DOCUMENT

Molteni Purchase Agreement (Details) $ in Thousands	6 Months Ended
Molteni Purchase Agreement (Details) $ in Thousands	Jun. 30, 2019 USD ($)
Molteni Purchase Agreement
Contract assets	$ 99
Contract with Customer, Asset Deductions	(99)
Contract with Customer, Asset	0
Deferred Revenue	313
Deferred Revenue, Deductions	(313)
Deferred Revenue	$ 0

XML 37 R28.htm IDEA: XBRL DOCUMENT

Molteni Purchase Agreement - Additional Information (Details) $ in Thousands			1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 21, 2018 EUR (€)	Mar. 21, 2018 USD ($)	Aug. 31, 2018 EUR (€)	Aug. 31, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Aug. 31, 2018 USD ($)
Purchase Agreement
Proceeds from Sale of Productive Assets	€ 2,000,000	$ 2,400
Revenue from Contract with Customer, Including Assessed Tax	€ 2,000,000	2,300	€ 950,000	$ 1,100	$ 502	$ 2,668	$ 1,447	$ 3,732
Revenue, Remaining Performance Obligation, Amount		$ 1,400
Convertible Debt			€ 550,000						$ 600
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Purchase Agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period		15 years

XML 38 R29.htm IDEA: XBRL DOCUMENT

Debt Agreements (Details)	1 Months Ended			3 Months Ended		6 Months Ended
Debt Agreements (Details)	Mar. 31, 2018 USD ($) $ / shares	Jul. 31, 2017 shares	Jul. 27, 2017 $ / shares	Jun. 30, 2019 USD ($) $ / shares	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) EquityInstruments $ / shares shares	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	Mar. 21, 2018 USD ($) $ / shares shares
Loss on debt extinguishment				$ (65,000)	$ 0	$ (65,000)	$ 0
Long-term Debt, Current Maturities				$ 1,333,000		$ 1,333,000		$ 527,000
Horizon Technology Finance Corporation
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares		366,668
Venture Loan
Debt Instrument Final Payment On Each Loan Tranchepercentage			5.00%
Venture Loan \| Horizon Technology Finance Corporation
Debt Instrument, Term		46 months
Interest Rate		8.40%
Venture Loan \| Horizon Technology Finance Corporation \| Prepayment occurs during the interest-only payment period
Percentage of prepayment penalty fee		4.00%
Venture Loan \| Horizon Technology Finance Corporation \| Prepayment occurs during the 12 months
Percentage of prepayment penalty fee		3.00%
Venture Loan \| Horizon Technology Finance Corporation \| Thereafter
Percentage of prepayment penalty fee		2.00%
Venture Loan \| Horizon Technology Finance Corporation \| London Interbank Offered Rate (LIBOR)
Debt Instrument, Interest Rate, Basis for Effective Rate		1.10%
Molteni Loan
Long-term Debt	$ 4,000,000
Molteni Loan \| Convertible Debt \| London Interbank Offered Rate (LIBOR)
Interest Rate						1.10%
Horizon Loan
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 7.20
Conversion Price, (in dollars per share) \| $ / shares	$ 7.20
Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares, Amount	$ 10,000,000
Debt Instrument, Periodic Payment	$ 1,600,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares									6,667
Long-term Debt									$ 2,400,000
Debt Instrument, Convertible, Number of Equity Instruments \| EquityInstruments						333,333
Molteni Purchase Agreement
Conversion Price, (in dollars per share) \| $ / shares				$ 1.50		$ 1.50
Variable Interest Rate				9.50%		9.50%
Convertible loan outstanding				$ 0		$ 0
Convertible Debt, Current				$ 0		$ 0
Debt Conversion, Converted Instrument, Shares Issued \| shares						448,287
New Horizon Warrants
Conversion Price, (in dollars per share) \| $ / shares									$ 7.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares									90,000

XML 39 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
	Aug. 31, 2019	Apr. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Sale of stock
Issuance of common stock in at-the-market offerings, net			$ 466
Proceeds from sale of common stock				$ 466	$ 0
ATM
Sale of stock
Issuance of common stock in at-the-market offerings, net (in shares)			329,656
Weighted-average price			$ 1.60	$ 1.60
ATM \| Maximum [Member]
Sale of stock
Issuance of common stock in at-the-market offerings, net	$ 4,000	$ 8,600

XML 40 R31.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended
Subsequent Events (Details) - USD ($)	Aug. 31, 2019	Jul. 31, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Subsequent Event
Proceeds from Issuance of Common Stock				$ 466,000	$ 0
Common Stock [Member]
Subsequent Event
Stock Issued During Period, Shares, New Issues			330,000
Subsequent Event
Subsequent Event
Proceeds from Issuance of Common Stock		$ 10,000
Subsequent Event \| Purchase Agreement [Member] \| Common Stock [Member]
Subsequent Event
Stock Issued During Period, Shares, New Issues	1,480,000
Proceeds from Issuance of Common Stock	$ 1,800,000
Subsequent Event \| Purchase Agreement [Member] \| Pre-Funded Warrants [Member] \| Common Stock [Member]
Subsequent Event
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,372,314
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Subsequent Event \| Purchase Agreement [Member] \| Placement Warrants [Member] \| Common Stock [Member]
Subsequent Event
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,852,314
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.07

EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

M@A);G^]:#4 6O$8Q7$ZQ'\&U&\(L&(X6BA;Y$5S/ 0Q>,!V!E;M'V(_@V@YA M%GQ'&PO=V]R:W-H965T&ULA9C;CMLV$(9? M1=!](G%XD+2P#=0NBA9H@$6*)M=:FUX+D417TJZ3MR]U6%<[,VQNK(/_(?_A MR)_&W-Q<]ZV_6#M$WYNZ[;?Q91BN#TG2'R^V*?N/[FI;_\W9=4TY^,ON.>FO MG2U/4U!3)Y"F)FG*JHUWF^G>8[?;N)>AKEK[V$7]2].4W8^]K=UM&XOX[<;G MZODRC#>2W>9:/MN_[/#W];'S5\E]E%/5V+:O7!MU]KR-?Q$/!SD%3(HOE;WU MJ_-H3.7)N6_CQ1^G;9R.CFQMC\,X1.D/K_9@ZWH)_-4]O;@ZJ_5:;ALXSR.3O9EO'?PO@ 6 +@'B#4_P;()4"B@&1V-J7Z M:SF4NTWG;E$W5^M:C@^%>)!^,8_CS6GMIN]\MKV_^[J38I.\CN,LDOTL@94$ MWBL.5"'_DR1^_KL)8$W %"_7\9*/EVR\G.+5.EZA)&:)F23MG 04. \J*J#0 MO!/%.E'4B49.9HE>39(B&U0AC>!=:-:%IBX,,8RUDE&G>3(2?;3RE!%4? FI@/ M5*-5H"P%ZZ,@/G#M]P4S1R&1$2H24J:!9U6D/(%2:H8@**6KHO&J<*)"!;P$ M:"BH%\!>!%T90;Q041IPPB-1 '4BL1,@DYC,"&R%JOPO/80UP1-62()H%5I: MGHR"HE%A- I*/I&"Q@DQ*@TFX(8GI*"(5!B1@N)/IZ305&0@5&J>D8)"4F%( M"@K 7&(Z,:*0$YZ1@D)284@*RD!98%PS(F5"%>)1*2@K%6:EH" D:T(E4@2: M"\'#4E!::DQ+04D(&M.2$07J SPJ@:)28U0"I:!G,K;"J#0$7B' LQ(H*S5F M)5 ,*HF)>F!44NE0!QEH(2DO\?KO@9*0]H",*%0D'I5 NU'\JMHOFG=.3)%C M*U0ELSQ4)1Z[0+&K,7;AYRTI(X' &P1XX@(EKL;$!0K33$I2(48%)O V IZY M8,C[3(<6EF>08G2S6@'_O MB"QM/,GW?SSLA\,;CKLNN3W+>>=O\"4$L#!!0 ( -: M#D\)U]WZ\ $ '<% 8 >&PO=V]R:W-H965T&ULC93= MCILP$(5?!?D!8O.;501(W515*[52M%7;:P>&@-;&U';"]NUK&Y82H-W>8,_X MG/$W!ISV0CZK&D![+YRU*D.UUMT!8U74P*G:B0Y:LU()R:DVH;Q@U4F@I3-Q MA@-"$LQITZ(\=;F3S%-QU:QIX20]=>6S>:>[>0LQ+,-/I49(A8( M&!3:5J!FN,$1&+.%#,;/L2::MK3&^?RU^@?7N^GE3!4DGT7^$L9\8>6/SG^$&S,@MB=FC$$RYIU="!SK;ZGFN:I%+TGAY?54?M-^(?0'&9AD^[LW)KI M5IGL+4_"%-]LG5'R.$B"F22X5QS7BO"/!)O])XA@$R)P_G .$6W[PTU_Z/S1 MW!\OFA@DL9.T3N(',2%DT/8+V"OI"Y67 MIE7>66CS-[EOOA)"@ZE(=J98;6[!*6!0:3O=F[D<[H(AT*(;KSD\W;7Y;U!+ M P04 " #6@ Y/#C!$_RH$ M% & 'AL+W=OWJKGS[ED.6:'+.C.E4^GC MRGUEBQT/VX".^"O3MWIT[;12WHWYWM[\>EBY?MLCG>N];5.DS<^'3G2>MYF: M?OPS)'7O;;:!X^O/[#]WXALQ[VFM$Y/_G1WL>>5&KG/0Q_2:VV_F]HL>!$G7 M&=3_IC]TWN!M3YHV]B:ON[_._EI;4PQ9FJX4Z8_^-RN[W]N0_S.,#N!# +\' MB/!A@!@"Q+,!P1 0/!L@AP ) KQ>>U?,;6K3];(R-Z?JY\,E;:<=6\AFN/;M MPVYTNO\U]:R;IQ]K%2^]CS;/@&QZA(^0T)\B6XRP.^$U[=\[P:E.;#AN@4U; M2 B$@TY\G67W,,NDHX*LENCBQ3A>T/$!&1]T\<$X/@#5[A'5(66'2!\H33## ME8I .3#$@B $!<&0",5,220I2>*22#I>D?$*ET2!DO2(',L- )-@!DU2C$@) MF-W#-!,U(:DFQ&I R3&;6Q:2F&&N"RUZ,IXN(P-N:8$@(.)A; M##%?,9!JARD5C@H]$<5\>C'WD2Q8X,W C-OY*8@BN,10F!*@1EN*BIF"JPR% M"7_T#D_%S3@50RM--.,RC+295\9Q>3@L#\==Y5+ ZE"40*Y(4$$-J7F,#*!%0FB!&54!B&D*HG\NP>YIDJHIV28:N$+]]F8"9O']2#$:0'(PQ- MX$=IIG)HEV02RY%0CB3>$H9&B*"(J4=0$KD_1['/:L3C[>KL_,&I^@4H(A,L8S(@M0>&-$P6IT;YRJHIV48Y=-)Y9 M##GM5OSYSRA.NP-_XD.*$^[@P_T; 87PE208Q=&7Y<-$4TVT17!L$?'<5S2] M%'/U?%WI]8X3WR^HKB'^L(SA:D= T*((1.()^RA/K\@;'744NCIUYTZULS?7 MTK;%&#V]GVV]\O:H!#S?L$7"B.=;MMCU)U?_I^\/TGY/JU-6ULZ[L=84W3'* MT1BKFY[[+\UPGG5ZN-_D^FC;R["YKOH#K/[&FLMP..?=3PC7_P%02P,$% M @ UH .3Z#$XB=^!0 !B !@ !X;"]W;W)KOF;G#'T>.I75PU4JM%&W5]IG$D]A:;%P@\?;;%S#Q MFGO/,+LOL7'.7#B7X?P86)Z+\FNUL[:>?#ODQ^I^NJOKT]U\7CWO["&K/A4G M>VS^\U*4AZQN-LO7>74J;;;M!AWRN0Z":'[(]L?I:MG]]EBNEL5;G>^/]K&< M5&^'0U;^M[9Y<;Z?JNG'#U_VK[NZ_6&^6IZR5_NGK?\Z/9;-UOQ:9;L_V&.U M+XZ3TK[<3S^KNXTQ[8!.\??>GJN;[Y/6RE-1?&TW?MO>3X/VB&QNG^NV1-9\ MO-L'F^=MI>8X_NV+3J_[; ?>?O^H_DMGOC'SE%7VH_>_VW>:-O#V29A_/15YU?R?/;U5='/HJS:$'4#] +H.H&AT@.D'F.][6(P."/L!X7 MIEF=K99E<9Z4E^EPRMI9I^["YFP]MS]V)Z?[7]/.JOGU?;70R_E[6Z>7K"\2 M?2NAH>0!2,Q0D@)).)1L@"2Z2N:-C:L7#;WH;KRY'1\S+Q=)U$F.G80=YX-4 MD#9*TAAV3P3@S-U&.B(^9&RYB(- MDYCI-D"7&$?T)-!6 FRQD%PG/W&9+N!>%OZ 6WA[MP"] P$G93C@I,X9<"K M" K\$==K?JQYRH$ZY4VY3:\9VC:Q:T>80TJ"2 6&._*CJ)>P:6XT:TX*=,VY MBF(C N$BA0YW&$@*4DDQ3-\K7Z&20I#24DJR:Q0DDNBC1(H,"V #L<%$CKS M0F%"*80HGAA*LF.DBY@>2N)#L+W7C,%=>=F0 LDLB<05YE$-/6&(*$01CD0E M4UV8DA+#9UCJK[/QU!E:P@!1B" B,Q+_9 >4@9DA=8[, ,*1S,#@4I)<(#, MF9RS76.6:,D2%;#K=]V+;MNH^(I& ^#0@CAO4Z";4=/QF,][((P24@YWF&!: M$DP%8HDC$:8H4(Y;3NU82H&U%$\-+0G&+S M@<-3 TAF)E0Q;Y]/-G2%T:41 MNOBM1B\:M27I)I8Q*1#QW/#4&5K"D-0(DN),26"9P'5A85YIQ"L>N;UHM'42 M:8HXB8%(M&Z\SM 2)J,&"RO%5XE:HE%FA40:F4 1SUR@:[(B#A;\!@,5#$+7 MQ,",U("12IPP"2Y%1KFF!D:71N@2F2O1)?L(V 4S%[$+9JX4CF0N1I=&Z!*9 M*]$UDKF$V45@'<0=$<#-(G:=,,(8(8 1Q6^L>]'@A/&;#9*H:69/S",U!;IF M5:4U?XZX0<(P=IPPPN@BL/KB4VU-$B?*Z,AQST:.1W, )R) 2.)$3'P"JR44 M($"' P05= 8(8;(0((L($))D&0D0PFPAR19QLT%^M)"7&BF0S$+% V;CE0U= M8;P0>FXG'MWZ5UXD82#NG5,@XL3TU!E:PDPAM.X29THRQ?6\DS!0" "%9\^: M %!XYT#\FP7OG!2)SH$ZH@, !4 _OWE? MVKXA_R,K7_?':O)4U'5QZ%Z0OA1%;9N2P:>FV,YFV^M&;E_J]FOLT,$ #&% & 'AL M+W=O1X^^\KR8K7RSE,^Q)+RN'P#$5^&G)^K>JOS<':=O*M M+$[-8GIHV_-3$#2;@RWSYE-UMJ?N/[NJ+O.VNZWW07.N;;X=&I5%P&$8!V5^ M/$V7\^'92[V<5Y>V.)[L2SUI+F69U_^L;%%=%U.:OC_X?-P?VOY!L)R?\[W] MP[9?SB]U=Q?UN,7VFI[4D?8-!\>?17IN'ZTF?RFM5?>UO M?MTNIF'OR!9VT_8A\N[GS:YM4?21.A]_CT&G]S[[AH_7[]%_'I+ODGG-&[NN MBK^.V_:PF*;3R=;N\DO1?JZNO]@QH6@Z&;/_S;[9HI/W3KH^-E71#'\GFTO3 M5N48I;-2YM]NO\?3\'L=X[\WPPUX;,#W!EW?'S60L8%\;V"&Y&_.AE1_RMM\ M.:^KZZ2^O:USWD\*>I)N,#?]PV'LAO]UV3;=T[$PQ492:"351D)RC*2J$Y/&CA&M2<4S(ADTDH$1<:;0 M*M.=.#:TPC/9*<2+/@13+/*$\'"#5"82N]P@Y3/*$B<7()J1;YH1),PSL3:3 MN&98]Q.Y$PV)2"CQN,$P(M%N%%)%=>0"9PTTLX0]5C#62'.-6+TF Y+6[PFH M(@^D"8.-(N7&1*Z9"'3CKM4U4K&)/6XP)4ECTJA)HQ&82NB:T2+?$&5 Q=0<8B2+QF,'D9$U.5:9TQNB89$O@V!>+:N MNEHDX^Y-1)>"[MH$$I-X5H)@> J IW'A*9J+<:3,_&]X"H:G@$VP\ .(9%[^C*/YX00,56-#!P^E/:>O]<%#63#;5Y=3V MYRP/3^^'<<_&H8W(\NE_\"4$L#!!0 ( -: M#D\BTJ, M@$ -(# 8 >&PO=V]R:W-H965T&UL=5-M M;]L@$/XKB!]0$N*F561;:EI5F[1)4:=MGXE]?E&!\P#'W;\?8,=S.^\+<,<] MSSUW'.F YM4V (Z\*:EM1AOGN@-CMFA "7N#'6A_4Z%1PGG3U,QV!D0904HR MOMGLF1*MIGD:?2>3I]@[V6HX&6)[I83Y?02)0T:W].IX:>O&!0?+TT[4\ W< M]^YDO,5FEK)5H&V+FABH,OJP/1R3$!\#?K0PV,69A$K.B*_!^%QF=!,$@83" M!0;AMPL\@I2!R,OX-7'2.64 +L]7]N=8NZ_E+"P\HOS9EJ[)Z#TE)52BE^X% MAT\PU7-+R53\%[B ].%!B<]1H+1Q)45O':J)Q4M1XFW<6QWW8;S97V'K #X! M^ RXCP V)HK*GX03>6IP(&;L?2?"$V\/W/>F",[8BGCGQ5OOO>3;Y#9EET T MQ1S'&+Z,F2.89Y]3\+441_X/G*_#=ZL*=Q&^^X_"=P3)*D$2"9)W!/L/):[% MW'U(PA8]56#J.$V6%-CK.,D+[SRP#SR^R=_P<=J_"E.WVI(S.O^RL?\5H@,O M97/C1ZCQ'VPV)%0N'._\V8QC-AH.N^D'L?D;YW\ 4$L#!!0 ( -: #D^N MDA/&PO=V]R:W-H965T&UL?5/;;MP@ M$/T5Q >$7=9MMRO;4C95U4J-M$K5Y)FUQS8*%Q?P.OG[ B:.VSA] 6:8<^;, M,.2C-H^V W#H20IE"]PYUQ\(L54'DMDKW8/R-XTVDCEOFI;8W@"K(T@*0C>; MCT0RKG"91]_)E+D>G. *3@;904IFGH\@]%C@+7YQW/&V<\%!RKQG+?P$]ZL_ M&6^1F:7F$I3E6B$#38&OMX=C%N)CP#V'T2[.*%1RUOHQ&-_K F^"(!!0N<# M_':!&Q B$'D9OQ,GGE,&X/+\POXUUNYK.3,+-UH\\-IU!=YC5$/#!N'N]/@- M4CT?,$K%_X +"!\>E/@J.]-%9RQ%?'.B[?>>RFWV3XGET"48HY3 M#%W&S!'$L\\IZ%J*(WT#I^OPW:K"783OWE'X%T&V2I!%@NR_):[%?/XG"5GT M5()IXS195.E!Q4E>>.>!O8Z/2%[#IVF_9:;ERJ*S=OYE8_\;K1UX*9LK/T*= M_V"S(:!QX?C)G\TT9I/A=)]^$)F_&PO=V]R:W-H965T&UL?5-AC]0@$/TKA!]P M=+M[>F[:)K=GC"::;,ZHG]EVVI(#I@+=GO]>H%RM6OT"S##OS9MA*"8T3[8' M<.1926U+VCLW'!FS=0^*VQL<0/N;%HWBSINF8W8PP)L(4I+E6?:**2XTK8KH M.YNJP-%)H>%LB!V5XN;'"21.)=W1%\>CZ'H7'*PJ!M[!9W!?AK/Q%EM8&J% M6X&:&&A+>K\[G@XA/@9\%3#9U9F$2BZ(3\'XT)0T"X) 0NT" _?;%1Y RD#D M97Q/G'1)&8#K\PO[NUB[K^7"+3R@_"8:UY?TCI(&6CY*]XC3>TCUW%*2BO\( M5Y ^/"CQ.6J4-JZD'JU#E5B\%,6?YUWHN$_IYDV";0/R!,@7P%W,P^9$4?E; M[GA5&)R(F7L_\/#$NV/N>U,'9VQ%O//BK?=>J]UM5K!K($HQISDF7\&_)6[%_%DD6_54@>GB-%E2 MXZCC)*^\R\#>Y_%-?H7/T_Z)FTYH2R[H_,O&_K>(#KR4[,:/4.\_V&)(:%TX MOO9G,X_9;#@N?@)02P,$% @ UH .3_NQ"0JT 0 T@, !D M !X;"]W;W)K&UL?5/;;MP@$/T5Q >$779ST)DXZ MIXS Y?F=_6.J/=1R%@X>4/V0E6]S>D=)!;7HE7_$X1-,]5Q3,A7_!2Z@0GA4 M$G*4J%Q:2=D[CWIB"5*T>!UW:=(^C#?\=H*M _@$X#/@+N5A8Z*D_(/PHL@L M#L2.O>]$?.+M@8?>E-&96I'N@G@7O)=B>\TS=HE$4\QQC.'+F#F"!?8Y!5]+ M<>1_P?DZ?+>J<)?@NW\H_(U@OTJP3P3[_Y:X%K/[(PE;]%2#;=(T.5)B;](D M+[SSP-[S]":_PL=I_RIL(XTC9_3A95/_:T0/0AK,= MQVPT/';3#V+S-R[> %!+ P04 " #6@ Y/XM_'J+,! #2 P &0 'AL M+W=O2V2O=@_(WC3:2.6^:EMC> *LC2 I"-YMK(AE7N,RC[V3*7 ].< 4G M@^P@)3.O1Q!Z+/ 6OSL>>=NYX"!EWK,6GL!][T_&6V1FJ;D$9;E6R$!3X-OM MX9B%^!CP@\-H%V<4*CEK_1R,KW6!-T$0"*A<8&!^N\ ="!&(O(Q?B1//*0-P M>7YG_QQK][6O88I>*_P06$#P]*?(Y* M"QM75 W6:9E8O!3)7J:=J[B/Z>8ZP=8!- 'H#+B)>Q:>>'N@OC=5<,96Q#LOWGKOI=SNLYQ< E&*.4XQ=!DS1Q#//J>@:RF.]!\X M78?O5A7N(GSW'X5_$&2K!%DDR#XL<2UF_U<2LNBI!-/&:;*HTH.*D[SPS@-[ M2^.;_ Z?IOV!F98KB\[:^9>-_6^T=N"E;*[\"'7^@\V&@,:%XR=_-M.838;3 M??I!9/[&Y1M02P,$% @ UH .3\Z*5\BT 0 T@, !D !X;"]W;W)K M&UL?5/;;MP@$/T5Q >$-;NY:&5;RJ:J4JF55JG: M/+/VV$8!XP!>IW_? 3N.TSIY 6:8<^;,,*2#L4^N ?#D1:O69;3QOMLSYHH& MM' 7IH,6;RICM?!HVIJYSH(H(T@KQC>;*Z:%;&F>1M_1YJGIO9(M'"UQO=;" M_CF ,D-&$_KJ>)!UXX.#Y6DG:O@)_E=WM&BQF:64&EHG34LL5!F]3?:'78B/ M ;\E#&YQ)J&2DS%/P?A69G03!(&"P@<&@=L9[D"I0(0RGB=..J<,P.7YE?UK MK!UK.0D'=T8]RM(W&;VAI(1*],H_F.$>IGHN*9F*_PYG4!@>E&".PB@75U+T MSAL]L: 4+5[&7;9Q'\8;GDRP=0"? 'P&W,0\;$P4E7\17N2I-0.Q8^\[$9XX MV7/L31&= -,4>&=!_:6QS=Y M"Q^G_8>PM6P=.1F/+QO[7QGC :5L+G"$&OQ@LZ&@\N%XC6<[CMEH>---/XC- MWSC_"U!+ P04 " #6@ Y/-NHS^K,! #2 P &0 'AL+W=OW<<^8CFT78 CCPIJ6U!.^?Z(V.VZD!Q>X,] M:'_3H%'<>=.TS/8&>!U!2K)LLWG#%!>:EGGTG4V9X^"DT' VQ Y*3_L0'P.^"QCM MXDQ")1?$QV!\J@NZ"8) 0N4" _?;%>Y!RD#D9?Q,G'1.&8#+\S/[AUB[K^7" M+=RC_"%JUQ7T0$D-#1^D>\#Q(Z1Z;BE)Q7^&*T@?'I3X'!5*&U=2#=:A2BQ> MBN)/TRYTW,=TYP9&8J?<]#T^\/6:^-U5P MQE;$.R_>>N^UW-X>&UL=55A;YLP$/TKB!]0 X% (D!J.DV;M$E1IW6?'7(!5!LSVPG= MOY]M*&/T\@7[SN_>N[/Q.1^$?%4-@/;>..M4X3=:]WM"5-4 I^I!]-"9E8N0 MG&ICRIJH7@(]NR#.2!0$6\)IV_EE[GQ'6>;BJEG;P5%ZZLHYE7\.P,10^*'_ M[GANZT9;!RGSGM;P _3/_BB-16:6<\NA4ZWH/ F7PG\,]X?0!3C$2PN#6LP] M6\I)B%=K?#T7?F S @:5MA34##=X L8LD\GC]T3JSYHV<#E_9__LBC?%G*B" M)\%^M6?=%'[F>V>XT"O3SV+X E-!B>]-U7^#&S #MYD8C4HPY;Y>=55:\(G% MI,+IVSBVG1N'<24-IS \()H"HCD@^I/>-P'YF] MJ:S3;85;,\DKX[V5X3;(R(2';] ,-RY\ MLU2/$YP@1@EB1Q#_5V*X*A'#W,DR0442A&"S$L$P,2ZR146V"$&R$L$P6UPD M1452A"!=B6"8#!?)4)$,(=BM1!!,&N B.U1DAQ"L#Q[#W#GX,,!O4(!0K(\> M!=TY^_#.30T_4B396@O;0A;-@8.L75M47B6NG>O)"^_<>A\CUUS^P<>^ M_9W*NNV4=Q+:M"C72"Y":#"Y! _F?V_,4S$;#"[:3E,SEV._' TM^NDM(/.# M5/X%4$L#!!0 ( -: #D\K^BC1P@$ #<$ 9 >&PO=V]R:W-H965T M)'TA>O]C?U3Z-WU-GF/O),)J;_PI7X [NG3B-2G$3?E$U&*O$S.*L M"/H^K4R&=9SY;V7Q@G0N2.\*R"04G'^DEI:Y5B/2T]GWU%_QYIBZLZE\,AQ% M^.;,&Y>]EIO]8TZNGFC&G"9,NL8L".+8%XDT)G%*_RM/X^7;J,-M*-^NU7=9 MG& 7)=@%@MT_+>[O6HQA#G&1+"J210@^W(E$,(?D3H2L+DZ ;L.3-:A2@PSC MLLHN4_&4AHO_"Y]&ZAO5+9,&791USR=<7!>.C?%2\"AL7Z[=WL] MO>4IL*J?QY0L_Q7E'U!+ P04 " #6@ Y/HFYS/\T! "7P)W?E[N"$NDZN4[R[X7&9XYPH"#H5Q"LPN-W@&SIV0+>/7K(D72T=< M[^_JK[YWV\N5:7B6_&=;FB;#1XQ*J-C S9LZ+^=OV%3W/[E:FZ[32Z2F/OJ+]) ME90&;"F[!]MP8Y^*)>!0&;=]M'LU#)[G7GS.!C1OM@5PY%U);7/:.M<=&+-E"XK;.^Q ^S\U&L6==TW#;&> 5Y&D M)$N3Y($I+C0MLA@[F2+#WDFAX62([97BYO<1) XYW=!KX%4TK0L!5F0=;^ ; MN._=R7B/S2J54*"M0$T,U#E]VAR.NX"/@!\"!KNP2>CDC/@6G,]53I-0$$@H M75#@_KC ,T@9A'P9OR9-.J<,Q*5]57^)O?M>SMS",\J?HG)M3O>45%#S7KI7 M'#[!U,\])5/S7^ "TL-#)3Y'B=+&+RE[ZU!-*KX4Q=_'4^AX#I/^E;9.2"=" M>D-@8Z)8^4?N>)$9'(@99]_Q<,6;0^IG4X9@'$7\YXNW/GHI-OM]QBY!:,(< M1TRZQ,P(YM7G%.E:BF/Z'SU=IV]7*]Q&^G:9_3Y9%]BM"NRBP.Z?%A]O6ES! M/-XF88N9*C!-W"9+2NQUW.1%=%[8IS3>R5_XN.U?N6F$MN2,SM]LG'^-Z,"7 MDMSY%6K] YL=";4+Y@=OFW'-1L=A-[T@-C_CX@]02P,$% @ UH .3],, M.=2W 0 T@, !D !X;"]W;W)K&UL=5/;;MP@ M$/T5Q >$-;N;IBO;4C95U4J-M$K5]IFUQS8*& ?P.OG[#MAQW<1Y 68XY\R% M(1V,?70-@"?/6K4NHXWWW8$Q5S2@A;LR';1X4QFKA4?3ULQU%D0925HQOME< M,RUD2_,T^DXV3TWOE6SA9(GKM1;VY0C*#!E-Z*OC0=:-#PZ6IYVHX2?X7]W) MHL5FE5)J:)TT+;%09?0V.1QW 1\!OR4,;G$FH9*S,8_!^%YF=!,2 @6%#PH" MMPO<@5)!"--XFC3I'#(0E^=7]:^Q=JSE+!S<&?5'EK[)Z TE)52B5_[!#-]@ MJF=/R53\#[B 0GC(!&,41KFXDJ)WWNA)!5/1XGG<91OW8;S9[R?:.H%/!#X3 M;F(<-@:*F7\17N2I-0.Q8^\[$9XX.7#L31&JK!UG&:'"E,W\9)7GCG@;WE\4W^P<=IOQ>VEJTC9^/Q96/_*V,\8"J; M*QRA!C_8;"BH?#A^PK,=QVPTO.FF'\3F;YS_!5!+ P04 " #6@ Y/P/5M M!64" !_" &0 'AL+W=ORZ<9%[VWBM3Y74&UZ1=_A$ M?A+YUKUPM?(&ED/=D%;4K'4X.6[<+5KO4*P##.)73:YB=._H4O:,O>O%M\/& M]75&A))2:@JL+A?R3"C53"J//Y;4'31UX/C^QO[%%*^*V6-!GAG]71]DM7%3 MUSF0(SY3^8A\D DAB%TS#LP@F6($YK@Q!>$<0/^388V*# M:0TFG4DR!#5"0"-YT.@QT4@C"P)8) )%(D D?1"))B*?4+*"56)0)094L@>5 M>**2KGQ8) %%DHF(>A/ !"E(D"YH:CK)J)L1@?TZQ8%0&]GS(1@QZ(EEK6@<:IA.B,# MFQ8M<2V:VA9%$G,_F$ M4[)S:\;N:'>8KMO S(__\'XT_\#\5+?"V3.III"9%4?&)%&I^$^JVDI]#0P+ M2HY2WR;JGO&PO=V]R:W-H965T U$T4M5(KK5*EO?;"L* 83&WODKY];<,B"LX-MHY&XCY7! 2)0-=$0\L %Z]:9FO"-2+?D%B8$#J4Q21Q'VO!AUI.W=(C.Q M$R\R=I6T[>'$'7'M.L+_'H&R,7=]]QYX:2^-U %49 .YP$^0K\.)JQ5:7*JV M@UZTK'].);E;N>+@@HE%([$#7)Z?G=_-KVK7LY$P".CO]M*-KF;NDX%-;E2^<+&KS#W$[G. MW/QWN %59_&MC?C./O?T^P)>$[ 2P*>>IE MIO(G(DF1<38Z?-K[@>A/[!^PVIM2!\U6F'>J>*&BMP)[.$,W;31KCI,&KS3^ MYVC1(.6_0+ 5@HU!L#8(/S (K :!,0C_JS+85#EI8J/I)T@4V"&A%1):(.$& M,FFB%23P4CLDLD(B"R3:0*(=Q(\^V*[8"HDMD'@#B7>0V(_MD,0*22R09 -) M=I!/B6^'I%9(:H&D&TBZ^_#1[N]"J_.@KYL?A%_:7CAG)M71,@>@9DR"\O,> M5+V-NN&6!85:ZFFBYGPZY]-"LF&^PM!RCQ;_ %!+ P04 " #6@ Y/RHQ" M(Y$# F$ &0 'AL+W=O9)DZ""C@+3M/]^S7@$C #35X*..?,Q>,S M,)V>>?Y6'!@3QD>:9,7,/ AQG%A6L3FP-"KN^)%E\I<=S]-(R,=\;Q7'G$7; MBI0F%MBV9Z51G)GS:;7VG,^G_"22.&//N5&9&9C&ENVB4R)>^'G-5$*N::CLO[-WEDAX&8GTL>%)4?TU-J=" M\%19D:&DT4=]C;/J>E;V/VDX 10!&@+XHP2J"/1"(*,$1Q&<"\$9);B*X#8$ M.AZ2IPC>A1",$GQ%\*_=I4 1@HN'NN)U.:KZ+B,1S:&%&918Z"-(787\]C'^!IDU8>0!F')()M( M 8MT 4@4I.OB <- %[/$,%3+IH_Q-5+66,8#]\7BE:05@9H MQX"/&W!0 TYEP.D8"+1L:XQ;8;*QVKFH"Q=QH9VR98T)6R[L.^)Y ZEXJ!^O M[P>T8_B$80:2\5$G/F) .V2/-<9K)0,0RC>*KHDK<4]]'/&(T\.M^[@00K>- MZR08H D&2(*:0I8UQN]4R[8UD3Q>A5I=A5I_A>HD%J*)A4ABFF9786\''<_K M%Z0/&]AB8N-]UT9B<0=,#+1NIXAS0[YX'R)((P)?.]HH*!CP@_W$' M2&NQ[7ZKNA:X1H!!:(^<&%RLI*_6D.(6 -<8V-=O(> : X)LH=[E%*C]=J1T M.%_ M0B(%BD,F,!%!C=\"P N,D"^!O2.L%"@SE$(1BH,N!H!$1JENB^WM[D0 MN+((SH O7)& *%(OY$*!.I\Y3C"2%RY=0+X0Z%"XN'0AN*&2N'X >=M15\\X MO')WK=9 D;)\7PV&PO=V]R:W-H M965T8VDYR??O:QN' ^-+\"?8R.]X9K-VD5TS>:(D0L]Z;NJ4KNV2L6SH.+4K4 M0/J$.]3R-T=,&LCXEIP*E.)1,!)TL[>$(_$7OM=H3OG('E4#6HI15N+8*.*_L9 M++? %0D2\:M"5SI:6T+*'N,WL?EV6-FNJ C5J&"" O+'!>6HK@43K^./(K6' M,T7B>'UC_R+%\/4K4H)"VU+JOZ,+JCE< M5,+/*'!-Y:]5G"G#C6+AI33PO7]6K7Q>%?\MS9S@J01O2.!GWTOP58+_D1#< M30A40O#H":%*"+43G%Z[-',#&]#!\6U \N0?ZY"!.77D>^XGY1' M+YGG1ZES$40*L^XQW@@3NU/(9@X! \+A!0Q5>*8JUMXLW9L>D,\1 "RT(O[+ MLKW/,BG4-]KE2P)_8E=L)@B,!($D""8$B>9WCXDDII48/]0,S^>8P-74;@R8 M1/NVVSDF\0.SH- H*)P)BC\Q)#+F1X\[&AL)X@<<[3'A2"4(-$,-D% S:S/' M+(#FYQSB@\0L)S'*20QR/KFB"R/!XG%#>8H+MJ M8EJ$FJ\&4 @B398SZGH-(B'/0O8/4$L#!!0 ( -: #D^QW@)=Y0( .X+ 9 >&PO=V]R M:W-H965T^7S*CK(L M:OK,'7&L*L+_IK1DYYF+W,O&2[$_2+WAS:<-V=,?5/YLGKE:>;W*MJAH+0I6 M.YSN9NX"37*$M8$A?A7T+*[>'9W**V-O>O%U.W-]'1$MZ49J":(>)[JD9:F5 M5!Q_.E&W]ZD-K]\OZIE)7B7S2@1=LO)WL96'F3MRG2W=D6,I7]CY"^T2BERG MR_X;/=%2X3H2Y6/#2F'^.INCD*SJ5%0H%7EOGT5MGN?V),:=&6R .P/<&XS\ MFP9!9Q#T!N%-/NSXL.=Q=-,@Z@RB!QW$'1\_ZB#I#!++P&MK:RYK12293SD[ M.[SMMX;HMD:31+7#1F^:VS=GZKZ$VCW-<>A/O9,6ZIBT9? 5DUA(]A%!/>&I M /HH,!1%BC^8XZ&#U4<"H;$5Q%V5_+;*(- +%=@!()K@7 $"X2@0&@$PD&] MD55OB+'K 3&!50^(":V*0$P$)Q2!"46 0&PEU#*Q86K#6/VSNDMD=XG\%C%( M) 83B8%$$BL1B!D-F27$6)VZ IC(2F?]@$X&Z5C=E-_V-2A, A8F 02L=DPA MQFK')<18[;B"F,@JS ,Z&<1879E#3 (79@069@0(6-V00HQUBTN B>U_$(BQ M;GK]@$[V0#PYI(/APHRMP@P.D0]_')&MI?C"?Y&/3K*P<^>*)=@[X1OLRRWO^DVTGX.^'[HA;.*Y-J M C)SRHXQ255%_2?U>W]0PW>_*.E.ZM=$O?-V FT7DC7==.WU(_[\'U!+ P04 M " #6@ Y/\TW1<,L" "/"@ &0 'AL+W=O_NP)=;W;AXDF?&5/#<-IUE^KLXEOLS:ZF,>,\Z_>3( M14N57HI3+'O!Z,$:M4V,DZ2(6UIWX69E]Q[$9L4OJJD[]B ">6E;*GYO6<-O MZQ"%+QM?Z]-9F8UXL^KIB7UCZGO_(/0JGKP)B8@U;*^,"ZHO5[9C36,\Z3A^C4[#B6D,Y_M&AM/1YN-:=O=Y&_R]FL $>#?!D@/._&J2C0?IJD-GDA\AL MJN^IHIN5X+= #&^KI^:C0'>I+N;>;-K:V6JO8^0I'8-B$BR$ S,NPH<.1<,1U+$NF:G/5T."T:=E3FMM3W8AB1AH7B_3C^Q=,,NOD# M4$L#!!0 ( -: #D\DGPT!O0( *H* 9 >&PO=V]R:W-H965T;$\8/$9G9G9YTAFUVY>)4GQI3S5A:57+@GI>JYY\G=B954SGC- M*OW+@8N2*KT41T_6@M&]#2H+#_M^Y)4TK]QE9O>V8IGQLRKRBFV%(\]E2<6_ M%2OX=>$B][;QG!]/RFQXRZRF1_:3J5_U5NB5UV79YR6K9,XK1[##PGU"\PW& M)L B?N?L*GOWCI'RPOFK67S;+US?5,0*ME,F!=67"UNSHC"9=!U_VZ1NQVD" M^_>W[%^L>"WFA4JVYL6??*]."S=QG3T[T'.AGOGU*VL%A:[3JO_.+JS0<%.) MYMCQ0MIO9W>6BI=M%EU*2=^::U[9Z[7-?PN# W ;@+L S?U1 &D#R'M ]&% MT 8$[P&![58CQ?9F0Q5=9H)?'=$<;TW-4X3F@>[^SFS:9MO?='NDWKTL<1)E MWL4D:C&K!H/[&.3?8]9C#.H0GJZ@*P-#9:SPF"*)!Q0 YAZQ&2,(AJL@8#.( MC2=W521P@@!,$-@$P5V"=" #P*0^3!*")"&0 V.K,&$%E,UQX$Q0B',$X$\ M$< SZ/BJP40]'CQQ[C'($0,<9,#18)*^EEDXH20!61* )8 3I&""]/$' _FP MSWR@AG!H(G_4SM@WGPFJ"4LC@"J:2 ':\0GA3PB&O80(4$4\_&9 M3 %[!R6?$ R[!Z6/"$Y'@N-X4B^&78;'+B/^U(L(=@]&C^O%L'LP?D!O"^I[ M/4S'>KW>B[QDXFB').GL^+FR$UIOMQO$GNP3H=>-I\O_4$L#!!0 ( M -: #D\H%_O%< ( & ( 9 >&PO=V]R:W-H965T96=%..]/..-O9]G?$*,P"H4G4[=LW"1R[LDY-R'7[$SH&ZLPYLY[VW1LX5:<]W, 6%GA%K$GTN-.O-D3VB(NIO0 M6$\QVJFDM@&!Y\U B^K.S3,5V] \(T?>U!W>4(<=VQ;1OTOX8S7I'(KW"_?9GZ]3B5> 7S4^LZNQ(YUL M"7F3DV^[A>M)0;C!)9<,2#Q.N,!-(XF$C#\CISLM*1.OQQ?V+\J[\+)%#!>D M^5WO>+5P$]?9X3TZ-OR%G+_BT0]TG='\=WS"C8!+)6*-DC1,_3KED7'2CBQ" M2HO>AV?=J>=YY+^DV1.",2&8$L3:]Q+",2'\2(CN)D1C0O3H"G!,@-H*8/"N MBKE"'.49)6>'#L>A1_+4^7,HMJN40;4[ZIVH)Q/14QYZ009.DFC$+ =,<(6) MO5O(RH3X$P(( 9.*P*9B&1CIFH;"1/A^JHGX+\OZ/LN-T-!:KE 11#?E"K5R M#1BH,-VP2!Q&FA\3E,!8\V,ABA*-:&TABD*[IW\@>J@[YFP) M%Y>ZNGKWA' LI'M/0G4EVOTT:?">RV$LQG1H>L.$DW[LYV#Z4Y'_ U!+ P04 M " #6@ Y/)X/D:0<" #(!0 &0 'AL+W=O*>G%R6^E'(X(B;(%BL4#&Z!7)S7C%$NU MY T2 P=.Y M:UJI-U"1#[B![R!_#!>N5FAVJ3H*O>A8[W&H3_YC>#QG6F\$/SL8Q6+NZ4JN MC+WHQ9?JY _HS4@_(/OE=!C6]$/K/Q,TSU)+XW%?\5[D"47&>B&"4CPGR]\B8DHY.+2H7B M5SMVO1E'>Y)$4Y@[()H"HCD@LK58D,G\(Y:XR#D;/6[O?L#Z%X?'2-U-J3?- M59@SE;Q0N_B/),CPR6V_ZUV)W;E./YNFB?W+;X[YAWG2]\*Y,JO=L7EW-F 25 M2/"@*FU56YT7!&JIIWLUY[:YV(5DP]0WT=R\B[]02P,$% @ UH .3ZJR MZ_I_ @ @ D !D !X;"]W;W)K&ULC5;OCJ,@ M''P5XP.LXG^;UN2VW6[;W"7-7N[N,VUI-:OB 6WWWOX J5%D-_9#!9P9YL<@ M87['Y)WF"#'KHRIKNK!SQIJ9X]!CCBI(GW"#:O[FC$D%&>^2BT,;@N!)DJK2 M\5PWJ@N3?,RKQ?6$#^S'P5EQR)@:<;-[ M"_J)V*]F3WC/Z51.185J6N#:(NB\L+^!V2X5> GX7: [[;4M4RW'^IK63NOY0 I6N+R3W%B^<). M;.N$SO!:LC=\WR!53VA;JOCOZ(9*#A=.^!Q'7%+Y;QVOE.%*J7 K%?QHGT4M MGW>E_Z"9"9XB>!W! U\2?$7PIQ("10BF$D)%"*<2(D6(IA)B18BG$A)%2*82 M4D5(IQ* ^TC.U2A.&[G<0RO(8#8G^&Z1]BMHH/C8P R(;7H4HW)7RI=\'U$^ M>LM\ .;.32@IS'.+\088;XA9FC#^$+,R88(AYL6$"8>8]1@#4@WS.L9XNLYF M@LYV@L[N:\\.#Z!+P3.GX$D%?Z 0F15\LX(O%8*!0JSEV&) &W;=%N/*GQ9F M"XSZN* '&O@)S'X"@Y]$\Q-,]=,"PS[.UT$K@UH:CL5>@E%Q .B@]1@4NMJ6 M?QUCO"C2:MP89@L"+9CM&.3'OF=>[]"\WJ%AO5-M&4.#E\]BC3 M'Y!&PO=V]R:W-H965T M%NP9FO(0P/EFYALSWV"\N*CB9WF4LG)^96E>+MUC59WFGE=N MCS*+RQMUDGG]SUX565S5M\7!*T^%C'>M499ZU/<#+XN3W%TMVK&78K50YRI- M[[P+?D<*R: 6^U.,4'^5U6_YQ>BOK.Z[WLDDSF M9:)RIY#[I7M+YAO>&K2(?Q-Y*0?73I/*JU(_FYOGW=+U&T8RE=NJ<1'7IS=Y M+].T\53S^$\[=?N8C>'P^MW[8YM\GJ$A.OH[+_(-YG6\(9)'6.KTK+]=;;GLE*9]E)3R>)?W3G)V_-%^W\W@PVH M-J"] 2.3!DP;L-Z 3D?@VH!_&/!) Z$-Q+64 FT0?$28-@BU0=@;B&E*D3:( MKHTPTP:S:PV(__[D_(^TP[:JND?>UM!#7,6K1:$N3M')X!0W:B-STI3IMAEM MJ[+]LZZCLAY]6S'*%]Y;XTEC[CH,'6 H\<>8SS8F-"!K&T)ZA%>S[*E2D.H= MM>P9%>,8]Q F&&,>($QHI -AHC'FT<908O!90WYF8\S3%7Z> 3_,F-\-A$%F MF,'%P%H/?. A8L;$=)"@A>0MY%,@?-_@\FC#S&JXSM'3E*-12AQ.B5LI,4:- MG+@5@[!Z>DTNZRMQSS9.T' (&Q$7,'$!$&>PAP#V$ >#&D_=)AHF-*-@*.$ M<)30BD*9J_4=\;#;JJ57.DRW"[R]C]3(.&$S,#>HPWV+')9'%H=PU+ M9ZO.>=6$&(SV.Y.WM-GQ,<;OR/R! ..?R?P1&E^3^5.W'_D1MML>_1H7AR0O MG5=552IK-XGV2E6RSLJ_J?,YRGC7WZ1R7S6787U==-N2W4VE3GK+U>OW?5>_ M 5!+ P04 " #6@ Y/@]Q;^(H" "K" &0 'AL+W=O>Q[,3*3$?T9I4 M\LF!LA(+.65'C]>,X+TFE84'?1]Y)!(JX*5)C8_D%Q&O]9;)F=>J[/.25#RGE;.P70#H")H MQ.^<7'EG[*A2=I2^JW&:N6/7V9,#/A?BA5Z_$5-0Y#JF^A_D0@H)5TYDCHP6 M7%^=[,P%+8V*M%+B]^:>5_I^;9[$L:'9"= 08$N0N1\1 D,(/@GA0T)H".&S M&2)#B)XE($- /4M>TRS=_146.$T8O3JL64 U5NL43)%\OYD*ZM>IG\D7P&7T MD@8H3KR+$C*818.!'0P$_BUF-<3$/ZL&,^[D :->P]>/,3=&@&_?%WR+E>". MQ)VM!3S?=F#]YN< ?KW,%P9TLP1]O[?[+"VH,?+[=KS.OED2=M2G'GJZ$ M*J43;4_6N3Y8>_$%F"Z!);Y6)['>IS_EFV/\)V;'O.+.C@JYV^L]^4"I(-*\ M/Y++ZB3_'-I)00Y"#6,Y9LWQV4P$K?L:XE,"E3?\$?#GG M?N; G5^$?*Z.G"OG)<^*:N$>E2IGGE=MCSQ/JHDH>:&?[(7,$Z6/\N!5I>3) MSI#RS*.$A%Z>I(6[G!O;HUS.Q4EE:<$?I5.=\CR1_U8\$Y>%"^ZKX4=Z.*K: MX"WG97+@/[GZ53Y*??):+[LTYT65BL*1?+]P[V"VH;0F&,3OE%^JSKU3E_(D MQ'-]^+I;N*3.B&=\JVH7B;Z<^9IG6>U)Y_'7.G7;F#6Q>__J?6.*U\4\)15? MB^Q/NE/'A1N[SH[ODU.F?HC+%VX+"ES'5O^-GWFFX74F.L969)7Y=;:G2HG< M>M&IY,E+Z0%4VGI>LLB?>^?: MD<6L&@SM8"B0:\S]$!/U( ]#"+0(3R?99DJQ3%=T0&=A?!UBC6"BH)?I$$-[ MB7Z(V P1 %.\&(:VG1D'K!N"!K@#'W7@&P?^5:5AKXX&$QI,83!^&!+2F\MF M""-X)@&:23#(9,IP?HCRP]M;$:$.(J0546_H#2;HU,@8Z;;B*DZ,QHD'<483 MG:(.IK=7"@17*_EX[&L+Z@X4QFN%D?<"()'B$1>H8.^ ?J)>7"; /I[MRH*Z MPP4_?J=B7%%P@Z16,!0+F%!CL7#-P% T+!IY@0 N&_B$;@ 7#B#*B4F_XJ%T M@$64@3\2"Q4WM!:"^JV%B8DZ@7R.FM#SN7!+'V5LQ6G0M4-Z5C; MQ?+.[)4]^PIF:T#L#WH1;=;&-_?-%OL]D8>TJ)PGH?2R8U:2O1"*Z^3)1+?H MJ!?G]I#QO:IO(WTOF^VQ.2A1VLW8:]?SY7]02P,$% @ UH .3\/Q;)^G M50 YSH! !0 !X;"]S:&%R9613=')I;F=S+GAM;.U]:W,;UY7@Y\6OZ/+8 M"5D%P #XE)5-%4U1"6Y[WGML/ +*4 MJ=JM=94I$NB^CW///>_''ZJJCC9Y^H]-Z?1VR*O'RMX9YDLF]_^^R8?1T>3832;3%\TO[S8/(RC:<^7.];3 M^_C=\SII?CF=C'YJ30Y/+^F-UUG\T/SV/LZJUC!NCO=)F1:XJF7T*JY;S^FF M!__K?VW=V>NT6L19]+2'Y"&MZC*&8=[% MJ]8&[J[O+MY%[_]\\>'MQ>75SW?7EQ=O;J/K=Y<]PUW">DI8RS6@P*?H/Y+G MYG,3^._%=#([/6M^<[DIRR8L^N Z&DUGHZ-ISR)>IUE21I?PWD-1ME;PKLA' M\6*1P#/PQ)*?[MN.K.E#LB[*.LT?HMLZKMO@_5O[-MR5\9)>>%[-BZSU[=V[ M]WUS%JL5W++;NEC\.HQNZ:I%-YNZJ@'_8<2>UZY62?F $_ZI+)[J1QQF'>>M MWO;IZ=WOU*OKQXLW%N\NKZ/;/5U=W MMT >?KY]%1U\>QA]&Z5Y=/=8;"I8>6N 5\D"[L:4[OQY'S+$5974U0^MK^/J MDG6?M\[O./\* '?AS62"* M+W1MS:_?E\DZ3I=1\@DH;P5'A\LLZD? R$6PJ19*%#6@_?9GWI= STLX&QP4 MM[U& C",\J1N/GJS1OQ&A,B2N$JB,GUXK$?%_6@#?]#HW0OHGEC/(TOC>9JE M=9JT#^5BL4!V5$7K^!E!VO%]N<&#R-(\Q2L.)P/$U4&J[_D*CA; F&7%4YPO MVL_=$'!C>=JLL(UQ]PEL8QF5"9SMIK7 )LATJ.>A'DL?6(@ZP*4M[J.LR!]& M=5*NHF4R[X'QH@W-SUA+#@2L9SUOMD[^"AC$1QCTHQFN>X%;%D9TZ;'(EDE9 M_3XZ6";WZ2*M#PD;Z^?V365J5C$U^W8RGDRF@"!E!!=VDT2P2Y8F?HBFLY,A M, <1+J)X4S\69?K/9/DRFAX/9Z,-'@'Q6L3K%.#1@9F;U28C]B$ Z(9CM158 M.V%/Z_Z\,7K)\L'[&#'F,:GQ[AT"F?XV^E[AJ.#<0J[[!NXY\)!]7;C#W(X? M'C$.8"W+(LOBLO)(OHLN;M^\_7/T9GKS^RU7TYN;VM@N8PQV\\&A_T5F8JS^\ M;F')95=%]6:ST MV2+OX34R0FN;USG07I X](%.QDS3 "8BA88'<4F;M'KLVBS/EN:+8M4]5K"< MSB?>)*Y-'>)AX0-&6ZGZ,JW3!9Y!F&Z1ON0Z MW A]PW1)_IO M0T&:X_PU07$#2?-' .5#HI<"A(\EW@1+_O(P.W=S>5__/GFS:NK#[>_CZY^^OGZ[F_1P:NKU]>7UW>' M1@C^#=0@(%5_?TM&$ACR M5RN]MU0Y?0Z)..__<.<[BJBM.P74G 8#\O$4EWA65507T7H#U (EHT7 03JN M ,%Q!'B6\ T 5.DT')C=O8W+?MVD9W=[O<.2B:?,>XZ]USL-".\[]M9W+/0M MH*/-&GY-/B7E(D4EQQQ.YQG\UG'L8O<\KY:=9(_SZGVG ?M]Q][ZSG98+ I0 M/,M*M G^JTY!G8+;$;=P]DO&&FX#;N_ \$IK'(RG /:F?BNB;:M;C[-(<+L&-Q.!.L:9$D2WD-8!;2Q>#V*)'<;YQTVR7LNXITE"$00TI9IM0"2L"GY5!1I M8+/.L]&O7^ =:XG<*AQUZ[^.)H1,X6V1U4F>1I>&.;SI8#2WB\=DNC%*XA&_+S(0>3OTUSV'ZGM_.HZ^8#6#.]BT&.('?P6) Q BCM; M^5;Q(MF0M8;$5OA>%6-\'VEJO*8'X*87)0&OA@M3*_"J)$M ZUD\ED4.*A8@ M7$+D#U[)TG\2TF]*HH1EFM2X6G.MR\T#S):!G@B?KT%G0*P<1J!*O4LV9?R[ M?SL_/I^]'-)FGWC58I/,GADO2#NAE1:P(20[2,S(*(8*88*X##/#_7Z,/^)S M93**%X J:*&%>>:;]6.:)[_[M^G9\4O$CK?Q,['I(:W[/BTKHG6DVL5KI#5, MI!$0/X]OQPXJZ-T$)"<*&$ ((%FD:&X 9K5,X.MQ!"? '(C(3I'#;HH\B>;B M!0&@/K#)'0YQL$/(J)0U1ID$[7I-X M 2FM[<\91&E@AL&/15P"^P*"39=G:"8$!I4Z2<= ,;-@X$/<"; BMEL\O*#K.(65T&?35\>CJ/W M9GOP=%HB(5@G"S)((]95#-5\0V9:Q& Q&L#AE-FS8JR=ME@3\6$T5 +X%%

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end XML 42 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 122 245 1 true 37 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.titanpharm.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.titanpharm.com/role/StatementCondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://www.titanpharm.com/role/StatementCondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.titanpharm.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.titanpharm.com/role/StatementCondensedStatementsOfStockholdersEquityDeficit CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 00400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://www.titanpharm.com/role/StatementCondensedStatementsOfCashFlows CONDENSED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.titanpharm.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 10201 - Disclosure - Stock Plans Sheet http://www.titanpharm.com/role/DisclosureStockPlans Stock Plans Notes 8 false false R9.htm 10301 - Disclosure - Net Loss Per Share Sheet http://www.titanpharm.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 9 false false R10.htm 10401 - Disclosure - Molteni Purchase Agreement Sheet http://www.titanpharm.com/role/DisclosureMolteniPurchaseAgreement Molteni Purchase Agreement Notes 10 false false R11.htm 10501 - Disclosure - Debt Agreements Sheet http://www.titanpharm.com/role/DisclosureDebtAgreements Debt Agreements Notes 11 false false R12.htm 10601 - Disclosure - Stockholders' Equity Sheet http://www.titanpharm.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 10701 - Disclosure - Subsequent Events Sheet http://www.titanpharm.com/role/DisclosureSubsequentEvents Subsequent Events Notes 13 false false R14.htm 20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.titanpharm.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.titanpharm.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies 14 false false R15.htm 30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.titanpharm.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.titanpharm.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies 15 false false R16.htm 30203 - Disclosure - Stock Plans (Tables) Sheet http://www.titanpharm.com/role/DisclosureStockPlansTables Stock Plans (Tables) Tables http://www.titanpharm.com/role/DisclosureStockPlans 16 false false R17.htm 30303 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.titanpharm.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.titanpharm.com/role/DisclosureNetLossPerShare 17 false false R18.htm 30403 - Disclosure - Molteni Purchase Agreement (Tables) Sheet http://www.titanpharm.com/role/DisclosureMolteniPurchaseAgreementTables Molteni Purchase Agreement (Tables) Tables http://www.titanpharm.com/role/DisclosureMolteniPurchaseAgreement 18 false false R19.htm 40101 - Disclosure - Organization and Summary of Significant Accounting Policies - Summary of Activity Product Returns and Discounts and Rebates (Details) Sheet http://www.titanpharm.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSummaryOfActivityProductReturnsAndDiscountsAndRebatesDetails Organization and Summary of Significant Accounting Policies - Summary of Activity Product Returns and Discounts and Rebates (Details) Details 19 false false R20.htm 40102 - Disclosure - Organization and Summary of Significant Accounting Policies - Summary of Maturities of Operating Lease (Details) Sheet http://www.titanpharm.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfOperatingLeaseDetails Organization and Summary of Significant Accounting Policies - Summary of Maturities of Operating Lease (Details) Details 20 false false R21.htm 40103 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.titanpharm.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Organization and Summary of Significant Accounting Policies - Additional Information (Details) Details 21 false false R22.htm 40201 - Disclosure - Stock Plans - Stock-based compensation expense recorded for awards (Details) Sheet http://www.titanpharm.com/role/DisclosureStockPlansStockBasedCompensationExpenseRecordedForAwardsDetails Stock Plans - Stock-based compensation expense recorded for awards (Details) Details 22 false false R23.htm 40202 - Disclosure - Stock Plans - Fair value of stock options (Details) Sheet http://www.titanpharm.com/role/DisclosureStockPlansFairValueOfStockOptionsDetails Stock Plans - Fair value of stock options (Details) Details 23 false false R24.htm 40203 - Disclosure - Stock Plans - Option activity (Details) Sheet http://www.titanpharm.com/role/DisclosureStockPlansOptionActivityDetails Stock Plans - Option activity (Details) Details 24 false false R25.htm 40204 - Disclosure - Stock Plans - Additional Information (Details) Sheet http://www.titanpharm.com/role/DisclosureStockPlansAdditionalInformationDetails Stock Plans - Additional Information (Details) Details 25 false false R26.htm 40301 - Disclosure - Net Loss Per Share (Details) Sheet http://www.titanpharm.com/role/DisclosureNetLossPerShareDetails Net Loss Per Share (Details) Details http://www.titanpharm.com/role/DisclosureNetLossPerShareTables 26 false false R27.htm 40401 - Disclosure - Molteni Purchase Agreement (Details) Sheet http://www.titanpharm.com/role/DisclosureMolteniPurchaseAgreementDetails Molteni Purchase Agreement (Details) Details http://www.titanpharm.com/role/DisclosureMolteniPurchaseAgreementTables 27 false false R28.htm 40402 - Disclosure - Molteni Purchase Agreement - Additional Information (Details) Sheet http://www.titanpharm.com/role/DisclosureMolteniPurchaseAgreementAdditionalInformationDetails Molteni Purchase Agreement - Additional Information (Details) Details 28 false false R29.htm 40501 - Disclosure - Debt Agreements (Details) Sheet http://www.titanpharm.com/role/DisclosureDebtAgreementsDetails Debt Agreements (Details) Details http://www.titanpharm.com/role/DisclosureDebtAgreements 29 false false R30.htm 40601 - Disclosure - Stockholders' Equity (Details) Sheet http://www.titanpharm.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.titanpharm.com/role/DisclosureStockholdersEquity 30 false false R31.htm 40701 - Disclosure - Subsequent Events (Details) Sheet http://www.titanpharm.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.titanpharm.com/role/DisclosureSubsequentEvents 31 false false All Reports Book All Reports ttnp-20190630.xml ttnp-20190630.xsd ttnp-20190630_cal.xml ttnp-20190630_def.xml ttnp-20190630_lab.xml ttnp-20190630_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 47 0001144204-19-040066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-19-040066-xbrl.zip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end